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1 INTRODUCTION 
Retinal dystrophies comprise a class of eye diseases displaying broad clinical and 
genetic heterogeneity. Common to all is the degeneration of photoreceptors and/or retinal 
pigment epithelium in the posterior pole of the eye, eventually resulting in significant loss of 
vision and in some patients even blindness.1 Retinal degenerative diseases range in severity, 
with a subform of retinitis pigmentosa (Leber’s congenital amaurosis) being the most severe, 
and the juvenile form of hereditary macular dystrophy (Stargardt disease) on the milder side of 
the spectrum.2 Due to technological advances in therapeutic options, the diagnostic importance 
and clinical implications brought about by genetic testing for retinal degenerative diseases have 
become increasingly significant. As a result, at least five retinal dystrophy phenotypes have 
been linked to mutations in the ABCA4 gene: Stargardt disease (STGD), fundus flavimaculatus 
(FF), cone-rod dystrophy (CRD), retinitis pigmentosa (RP), and age-related macular dystrophy 
(AMD).3 
1.1 STARGARDT DISEASE (STGD) 
This dissertation was part of a larger study focused on Stargardt patients with variants 
in the ABCA4 and CNGB3 genes. Stargardt disease was first characterized by German 
ophthalmologist Karl B. Stargardt in 1909 and is one of the most common forms of autosomal 
recessive macular dystrophy, with a prevalence of 1: 10,000 to 1:15.000.9 In addition to an early 
onset typically in the first two decades, further hallmarks include progressive loss of central 
vision, bilateral atrophy of the foveal retinal pigment epithelium and neuroepithelium, delayed 
dark adaptation, as well as the appearance of yellowish flecks surrounding the macula and 
retinal periphery (Stargardt, 1909 in Lewis et al.11). Additional clinical symptoms observed are 
the presence of a dark or silent choroid, as well as a hypofluoresent peripapillary ring.3 To date, 
three molecular distinct origins have been described for Stargardt disease. Autosomal recessive 
STGD1 is caused by homozygous or compound heterozygous mutations in ABCA4, located on 
chromosome 1p22; 4 autosomal dominant STGD3 is linked to a mutation in the ELOVL4 gene 
(chr. 6q14), 5 whereas autosomal dominant STGD4 has been linked to mutations in the PROM1 
gene (chr. 4p15.32).6  
The ABCA4 gene, first identified in 1997, is located on human chromosome 1p22 and 
contains 50 exons.10 The protein product of ABCA4 belongs to a class of ATP-binding cassette 
(ABC) transporters, which are ubiquitously expressed integral membrane proteins and 
constitute the largest family of eukaryotic transmembrane proteins.12 The ABC transporters 
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employ energy generated from ATP hydrolysis in order to transport various substrates such as 
metabolic products, lipids and sterols, as well as drugs, unidirectionally across cellular 
membranes.13, 14 Seven subfamilies of mammalian ABC transporters are currently known, with 
ABCA4 constituting member 4 of the ABCA subfamily.12 ABCA4 is a single-chain protein 
consisting of 2,273 residues organized in two tandem halves (Fig. 1).19 Each half includes an 
exocytoplasmic domain, a six helical transmembrane domain, and a cytoplasmic domain upon 
which the nucleotide binding site resides.19 The exocytoplasmic domains are joined by a 
disulfide bridge, display multiple glycosylation sites, and the cytoplasmic domain is 
phosphorylated.19,20 
 
 
Figure 1: ABCA4 structure  
Two tandem halves each with an exocytoplasmic domain (ECD1; ECD2), a cytoplasmic domain (CD1; CD2), and a 
nucleotide binding domain (NBD1; NBD2); Stars: glycosylation sites; Spheres: phosphorylation sites 
Figure borrowed from Tsybovsky et al., 2013 (Fig.2a) 19 
 
ABCA4 is expressed exclusively in the retina photoreceptors, 15 primarily on the rims 
and incisures of rod outer segments discs, 16 but has also been found in foveal and peripheral 
cone cells.17 The discovery of the ABCA4 gene, and with it the growing understanding of the 
role of the ABCA4 protein in the visual cycle, served to shift the understanding of Stargardt 
disease from being a disease of the retinal pigment epithelium (RPE) to one of rod 
photoreceptors.18 Biochemical experiments, phenotype analysis of mice deficient for ABCA4 
(Abca4 -/-), as well as clinical studies of macular degeneration patients, have aided in 
conceptualizing the role ABCA4 plays in the visual cycle.22 Quasi and Molday were able to 
show that ABCA4 transports N-retinylidene-phosphatidylethanolamine (NRPE) from the 
exocytoplasmic to the cytoplasmic side (Fig. 2), and it is the only mammalian ABC transporter 
known to be an importer.23   
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Faulty transporting due to a mutated protein, as appears to be the case in Stargardt 
disease, results in the accumulation of N-retinylidene-phosphatidylethanolamine and all-trans-
retinal in the interdiscal space, increasing the likelihood of a second molecule of all-trans-
retinal binding to NRPE and thereby forming A2E, an oxidative component of lipofuscin (Fig. 
2).24 A build up of lipofuscin deposits, as is seen in retinal degenerative patients, is suspected 
to have toxic effects on the retinal pigment epithelium (RPE), including disrupting membrane 
permeability, lysosomal dysfunction, and apoptotic signaling leading to photoreceptor death.3  
 
 
Figure 2: Proposed biological role of ABCA4  
Left: rod outer segment disc with a functional ABCA4; Right: inactive ABCA4; Circles with carbon backbone: all-
trans-retinal (black) and all-trans-retinol (red); RDH: all-trans-retinol dehydrogenase 8. RPE: retinal pigment 
epithelium.  
Figure borrowed from Tsybovsky et al., 2010 (Fig.7)22 
 
ABC transporter genes typically encode structural proteins and genetic mutations may 
lead to a significant reduction or even complete loss of protein function. The resulting disorders 
are inherited in an autosomal recessive or X-linked recessive fashion.14 Experimental data have 
shown that disease severity is often inversely proportionate to the activity level of the ABCA4 
protein (Fig. 3).25  In other words, depending on whether an ABCA4 allele produces a normally 
functioning protein, a damaged protein, or complete lack of protein, the resulting phenotype 
can remain unaffected, or vary from mild to severe. On the severe end, mutations causing 
misfolded or truncated proteins are characterized by an early disease onset, primary 
photoreceptor loss, and secondary RPE damage.25 In contrast, milder mutations may initially 
leave photoreceptors intact, yet the diminished ABCA4 functioning results in gradual 
accumulation of toxic by-products in the RPE consequently leading to photoreceptor death.25 
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Figure 3: Progressive phenotypes resulting from ABCA4 mutations 
Left: triangle representing ABCA4 activity; Genotype: (both alleles): null: no functional protein, hypo: reduced 
functioning alleles, WT: wild-type/normal alleles; Arrows: association between phenotypes and genotypes; 
Brackets: both STGD and FF can be caused by either genotype.  
Figure borrowed from Shroyer et al., 1999 (Fig.3)25 
 
The residual ABCA4 function model, as described above (Fig. 3), has been criticized in 
for being “oversimplified”.22 Studies in tadpoles, for instance, have shown that protein 
mislocalization may be a contributing factor in disease severity.26 Moreover, Cideciyan et al. 
were able to demonstrate that several patients with missense and splicing mutations showed 
greater phenotype severity than those with truncating mutations, and thus proposed a two-
pathway model of understanding ABCA4 disease pathogenesis. 1 Initially, conventional loss-of-
function occurs. As a result, stress is placed on the cellular degradation system, subsequently 
inducing a toxic gain-of-function response, and eventually apoptotic signaling.1 As further 
evidence of the complexity surrounding the genotype-phenotype correlation, other groups have 
shown that non-ABCA4 modifying factors are also instrumental in determining the level of 
visual functioning in patients with confirmed ABCA4 eye disease.27 
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1.2 BACKGROUND 
As outlined below (Table 1), the variants (N=21) for this study were selected from a 
pool of possibly pathogenic variants found in a cohort of 335 patients clinically diagnosed with 
Stargardt disease who had undergone diagnostic testing at the Institute of Human Genetics, 
University of Regensburg between 2008 and 2015. The sequencing analysis included the coding 
regions and canonical site junctions of ABCA4 and CNGB3. Although the majority of variants 
stemmed from Stargardt patients, three additional variants identified in cone-rod dystrophy 
patients were also included. 
 
Table 1: Sequence variants identified in 197 Stargardt disease patients tested between the years 2009 and 2012 at the 
Institute of Human Genetics, University of Regensburg (2009-2012) * minor allele frequency 
 
The unique variants with a minor allele frequency (MAF) <1% in controls were further analyzed 
in silico to assess for possible spliceogenic effects. Based on positive predictive results from 
several bioinformatics tools, seventeen ABCA4 variants, one CNGB3, as well as the three 
ABCA4 variants found in cone-rod dystrophy patients (not included in the above table) were 
selected for subsequent in vitro functional investigations. 
 
 
 
 
 
 
 
 
 
Gene Unique Variants Unique variants with MAF* 
in controls <1% 
Novel unique 
variants with 
MAF* in 
controls <1% 
ABCA4 136    116 32 
CNGB3   16      10   8 
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1.3 CNGB3 
The CNGB3 gene is located at 8q21.3, contains 18 exons31 and encodes for a cyclic 
nucleotide-gated (CNG) cation channel.28  CNGs belong to the superfamily of Voltage-gated 
Ion Channels (VIC) and play a crucial role in visual and olfactory transduction.28 Specifically, 
they are responsible for the generation of light-evoked electrical responses in the red, green, 
and blue sensitive cones.7 In the absence of light, channels are held open by cGMP, maintaining 
an inward current; light causes cGMP to be hydrolyzed, upon which the CNG channels close, 
hyperpolarizing the cell and transduction commences.29 CNG channels found in the outer 
segments of cone cells in the human retina consist of two subunits: α (ion-conducting) and β 
(modulatory), and are encoded for by CNGA3 and CNGB3 respectively.29, 30  Even though its 
function is considered to be only modulatory and the mechanism is not yet fully understood, 
the β subunit appears to vital to cone functioning and survival.29 CNGB3 mutations are most 
commonly linked to achromatopsia and juvenile macular degeneration.7, 8 Some evidence exists 
that mutations in the β subunit may result in gain-of-function leading to Ca2+ overload, in turn 
causing cytotoxicity and increased susceptibility to cell death.32  
1.4 CONE-ROD DYSTROPHY 
Cone-rod dystrophy (CRD) is a rare form of pigmentary retinopathy with a prevalence 
of 1:40,000.33  It is characterized by pigment deposits in the macula, decreased visual acuity, 
photophobia, dyschromatopsia, progressive loss of peripheral vision, and night blindness in 
later disease stages.33 Cone-rod dystrophy can be differentiated from rod-cone dystrophy 
(retinitis pigmentosa, RP) in that the latter typically presents in initial stages with night 
blindness, whereas the clinical course of cone-rod dystrophy is more severe with an earlier 
onset of blindness.33  Although a number of genes have been linked to cone-rod dystrophy, 
including ABCA4, CNGB3, CRX, KCNV2, and RPGR, a recent study published that 65% of the 
CRD patients in their sample were found to have ABCA4 mutations and suffered the fastest 
progression to legal blindness.34 
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1.5 SPLICING REGULATION AND DISEASE 
Research in the previous two decades has demonstrated that correct splicing, a process 
by which the non-coding introns are removed and the exons joined together to form the mature 
mRNA (messenger RNA), relies on the correct recognition of exons. 35, 36, 37, 38  Involved in this 
process are so-called “cis” elements including the highly conserved consensus sequences at the 
intron 5’ donor splice site (GU), the 3′  acceptor site (AG), the polypyrimidine tract, and the 
branch point sequence slightly upstream from the 3′  end. 92  “Trans” elements refer to the 
spliceosome snRNP (small nuclear ribonucleoproteins) and the enhancer or silencer elements 
that either activate or repress splicing. 92  The 5′  splice site (Fig. 4) beginning with GU is 
comprised of nine partially conserved nucleotides from nucleotide position -3 to +6 found at 
the exon-intron border (Fig. 4).39 Nucleotide changes in the highly-conserved, i.e. the canonical 
-1, +1, and +2 sites, are very likely to affect splicing, 40 whereas less conserved sites, such as 
the -3, can tolerate more variance. 41 
 
Figure 4: Splice site consensus site motif* showing intron 3′ acceptor (AG) and 5′ donor (GU) sites, based on an 
updated collection of 201,541 human 5′ splice sites. The varying height of each nucleotide represents the degree of 
conservation at that position.  
Figure borrowed from Roca et al., 2013 *modified (Fig. 1b) 39                                                                                                
 
The 3′  terminus (Fig. 5) consists of an AG dinucleotide acceptor site, a 14-26 nucleotide 
polypyrimidine tract, and the branch point located 18-40 nucleotides upstream from the 3′ 
junction. 92, 94 
 
 
Figure 5: 3′ terminus with (AG) acceptor site, the CT (CU) rich polypyrimidine tract and branch point 92 
Figure borrowed from Zhang et al. 2007 *modified (Fig. 1C) 93 
  3′              5′ 
Branch point 
YNYURAC 
Polypyrimidine tract              3′ splice site 
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The major human spliceosome is made up of five types of small nuclear ribonucleoproteins 
(snRNP) and numerous core proteins.96 Upon recognition, the spliceosome machinery 
hybridizes at the 5′ and 3′ splice sites and in a series of catalyzed steps, two transesterification 
reactions carry out intron excision and subsequent exon ligation (Fig. 6).97 
 
 
 
Figure 6: Model for the major human spliceosome assembly and function 
 
U1 and U2 snRNPs bind to the 5′ splice site and branch point respectively. The U2-auxiliary factor heterodimer 
interacts with the polypyrimidine tract (Y) and 3′ splice site to form complex A. The catalytic complex C is formed 
when the U4/U5 snRNPs bind, leading to a remodeling and removal of the U1 and U4 snRNPs. Two 
transesterification reactions ligate the exons and release an intron lariat, which is then degraded. The spliceosome is 
disassembled and recycled for use on another intron. 
rectangles: exons; dashed line: intron; A: branch point; Y: polypyrimidine tract; ESE: exonic splicing enhancers; 
ESS: exonic splicing silencers 
red, black, & orange stars: show mutated component associated with neoplasias, retinitis pigmentosa and MOPD1 
respectively (not relevant here) 
Figure borrowed from Singh & Cooper, 2012 (Fig.1)44 
 
Research has shown that exon recognition and splicing efficiency are equally dependent 
on both the 5′ and 3′ splice sites, yet high 5′ splice site complementarity to the U1 complex and 
a lengthy polypyrimidine tract seem to be especially important for spliceosome affinity.95 In 
addition to the highly conserved consensus sequences at intron-exon borders, other splicing 
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regulatory elements found within exons and introns can act as either splicing enhancers or 
silencers.42  
Correct gene expression requires extraordinary precise choreography among all splicing 
elements in order to facilitate correct exon recognition and intron removal, and variations in 
nucleotides may disrupt the splicing machinery. In general, the higher the degree of 
conservation at the site where the variant/mutation occurs, the more severe the consequence.  
Hence, the nature of the outcome depends on the extent to which correct splicing can still occur, 
as well as on what molecular changes are brought forth by the change. Most frequently, exon 
skipping is seen (Fig. 7), but cryptic splice site activation is also very common (Fig. 8).39 
Whereas total intron retention is rare, partial intron sequence may be included in the mRNA as 
a result of cryptic splice site activation or mutations within the intron, creating a pseudoexon 
and possibly leading to a frameshift (Fig. 8 & 9).39, 44  
 
 
Figure 7: Mutations that reduce the strength of 5′ or 3′ splice sites decrease exon identification and are therefore 
likely to result in exon skipping. GT: 5′ splice site; AG: 3′ splice site; Y: polypyrimidine tract; A: branch point; ESE, 
ISE: exonic & intronic enhancers; ESS, ISS: exonic & intronic silencers (here not relevant) 
Figure borrowed from Singh & Cooper, 2012 (Fig.2a) 44 
 
 
Figure 8: Mutations that activate cryptic splice sites, i.e. sequence identical to the consensus site that is not used for 
splicing, but which increases in strength due to a mutation. This may result in the inclusion of extra sequence in the 
spliced mRNA, thus disrupting the reading frame (frameshift).  GT: 5′ splice site; AG: 3′ splice site; asterisk: enhancer 
element; blue line: normal splicing pattern; red line: splicing pattern due to mutation; dashed red rectangle: inclusion 
of intronic sequence.  
Figure borrowed from Singh & Cooper, 2012 (Fig.2c) 44 
15 
 
 
 
Figure 9: Mutations in intron (indicated by arrow) may also lead to inclusion of intronic sequence creating a 
pseudoexon. Extra sequence may result in a frame shift. GT: 5′ splice site; AG: 3′ splice site; blue line: normal 
splicing pattern; red line: splicing pattern due to mutation; dashed red rectangle: inclusion of intronic sequence; 
Figure borrowed from Singh & Cooper, 2012 (Fig.2c) 44 
 
 
Possible pathological consequences on the molecular level include premature stop 
codons resulting in a truncated protein, as well as insertions or deletions of amino acids leading 
to frame shifts.45 The outcome depends largely on which scenario is brought about by the 
nucleotide change (Fig. 7-9). To date, most recorded data on splicing mutations remains at the 
genomic sequence level, 91 posing a problem for both researchers and clinicians in interpreting 
and predicting the functional implication of the mutation. These challenges are particularly 
multifaceted for the ABCA4 gene given its wide allelic diversity, 46 which not only displays 
variance in the resulting phenotype,47 but also in the pathogenic severity.48 ABCA4 disease 
alleles are found at a frequency of approximately 1 in 50 in the general population, 47   and many 
sequence variants are intronic, making them difficult to interpret.46 The complexity is 
compounded by tissue inaccessibility preventing direct RNA analysis of possible pathological 
isoforms in the retina of living patients. 
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1.6 ABCA4 VARIANTS AND EFFECT ON SPLICING 
Research from previous decades demonstrated that up to 15% of point mutations leading 
to human genetic disease are located within the highly conserved splice site regions, 49 and 
current research supports these findings.98 A growing number of studies are expanding the 
scope to focus on how nucleotide changes both within the coding region, as well as those at 
splicing regulatory element sites, may affect splicing and what role they play in disease 
pathogenesis.43,50,51 In line with broader data available on splicing mutations,  the Human 
Genome Mutation Database shows that ≈15% of first-report mutations in the ABCA4 gene are 
classified as splicing mutations (Table 2), yet descriptive data regarding the nature of 
spliceogenic variants remains scarce due to lack of in vitro analyses, as will be discussed further 
on. 
 
 
Mutation  Type Number of 
Mutations 
Missense/ 
nonsense 
536 
Splicing 117 
Deletions 107 
Insertions 23 
Indels 7 
Com. rear. 1 
Total 791 
Table 2: ABCA4 mutation types and number  
http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ABCA4; Public Version 13.01.2019 
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1.7 IN SILICO PROGRAMMES TO PREDICT VARIANT EFFECT ON SPLICING 
Numerous web-based prediction tools are available for performing bioinformatic 
analyses of the potential effect a variant may have on splicing. This study incorporated five 
such programmes for the in silico variant analysis (Table 3). 
 
 
Software  Application Provider 
Gene Splice Finder Splice site predictor (scale 0-15) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
Human Splicing Finder Splice site predictor (scale 0-100) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
Neural Network Splice site predictor (scale 0-1) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
MaxEntScan Splice site predictor (scale 0-12) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
Splice Site Finder Splice site predictor (scale 0-100) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
Table 3: Software used for in silico predictions in this study 
In silico analyses have demonstrated effectiveness in their ability to predict the disruption of 
canonical donor and acceptor sites due to single nucleotide changes, with some studies showing 
up to 100% specificity and sensitivity for certain programmes.73   However, not all studies have 
been able to obtain such high accuracy rates, and wide discrepancy has been reported in some 
cases.52,54 Moreover, interpreting the effect of nucleotide changes on the enhancement or de 
novo creation of cryptic splice sites has proven difficult. Deciphering how sequence variations 
in enhancer or silencer splicing regions may affect splicing poses an even greater challenge.40 
 Researchers caution against relying on a single in silico prediction programme,54 
others stress in vitro analysis’ indispensability in characterizing the effect of variants deemed 
spliceogenic by such programmes,40, 73 yet both approaches present several challenges. 
Interpreting the results of numerous programmes can be complex, as each tool relies on 
different baseline algorithms and scoring systems and may vary in the amount of input sequence 
required or analytical procedures utilized.40 Similarly, functional analyses, while providing an 
in vivo picture of possible effects on splicing, can be time and resource consuming, particularly 
when tissue is limited or inaccessible, as is the case with ABCA4.  An effective means of 
optimizing the process could be implementing in silico tools for initial selection and 
18 
 
prioritization of variants, which are subsequently analyzed in vitro in hopes of characterizing 
their potential putative in vivo effect.52, 53, 54 
1.8 PURPOSE OF STUDY 
This study carried out in vitro analyses of a selection of ABCA4 variants found in patients 
with retinal dystrophy (STGD and CRD) which had been predicted in silico to affect splicing. 
Because ABCA4 and CNGB3 are transcribed exclusively in the retina, it is not feasible to 
investigate splicing via direct RNA analysis from native tissue. To circumvent this problem, an 
in vitro exon trapping method was employed based on work done by Cepko et al. 55 This 
approach capitalizes on the highly conserved sequences flanking splice sites and implements 
transmissible expression vectors to generate and recover genomic inserts.56, 57 Following 
replication and selection in E.coli, the pSPL3b vector containing the construct was transfected 
in transient cells, the RNA isolated, reverse transcribed, and RT-PCR amplified. Visualizing 
the products via gel electrophoresis allowed for initial comparison of splicing activity between 
the normal allele and mutant variants. 
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2 MATERIAL 
2.1 ANALYZED VARIANTS, SOURCES, AND CHARACTERISTICS OF CONSTRUCT 
 
Patient 
ID 
(Medistar 
No.) 
Working 
ID 
Variant Geno-
type 
Exon Product 
size 
(bp) 
Included 
5′  
intron 
seq. (bp) 
Included 
3′  
intron 
seq. (bp) 
Phenotype 
18962 A c.67-1G>C Homo 2 263 103 54 STGD 
16843 G c.67-2A>G Het 2 263 103 54 CRD 
17412 U c.160+2T>C Het 2 263 103 54 STGD 
         
21066 B c.4773+3A>G Het 33_34 506 138 50 (131 
between) 
STGD 
         
15977 C c.4919G>A Het 35 404 141 81 STGD 
17002 D c.5018+2T>C Het 35 404 141 81 STGD 
         
17002 E c.6386+2C>G Het 46_47 475 100 93 (73 
between) 
STGD 
         
15485 F* CNGB3 
c.991-3T>G 
Het 9 327 176 74 STGD 
         
17716 H c.179C>T Het 3 358 67 149 STGD 
         
15282 I c.1239+1G>C Het 9 431 112 180 STGD 
         
20364 J c.1937+1G>A Het 13 411 85 149 STGD 
21529 K c.1819G>A Het 13 411 85 149 STGD 
         
15023 L c.2894A>G Het 19 415 54 186 STGD 
         
16178 M c.3808G>T Het 25 478 151 121 STGD 
         
15286 N c.4352+1G>A Het 29 407 192 116 STGD 
         
14686 O c.4354G>T Het 30 424 96 141 STGD 
16827 P c.4457C>T Het 30 424 96 141 STGD 
         
16272 Q c.5196+1G>A Het 36 358 95 85 CRD 
17575 R c.5189G>A Het 36 358 95 85 STGD 
         
20882 S c.5312+1G>A Het 37 390 184 90 CRD 
         
16518 T c.6732G>A Het 49 301 114 100 STGD 
Table 4: Analyzed variants, sources, and characteristics of construct 
* All variants in ABCA4: NM reference NM_000350.2, except *F: CNGB3 NM reference NM_019098.4  
STGD = Stargardt disease; CRD = cone-rod dystrophy  
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2.2 PATIENTS  
Between the years of 2008 and 2015, DNA samples of 335 Stargardt patients (191 
female, 144 male) were analyzed for ABCA4 mutations in the 50 coding exons and adjacent 
intronic sequences as part of routine diagnostic screening at the Institute of Human Genetics, 
University of Regensburg. Informed written consent was obtained from each patient in 
accordance with established guidelines of the German Medical Association, the German 
Society of Human Genetics, and the German Genetic Diagnosis Act of 2010, agreeing to the 
use of their DNA for research purposes aimed at underlying genetic cause of their disease. 
Genomic DNA was isolated from peripheral blood lymphocytes. 
2.3 OLIGONUCLEOTIDES/PRIMER  
Gene/Exon /Restriction Site Sequence 
 
ABCA4-ex02-F-EcoRI gaattcACTGCACACATGGGATCTGA 
ABCA4-ex02-R-BAMHI ggatccAGGCCCAGACCAAAGTCTCT 
ABCA4-ex03-F-EcoRI gaattcTCCTAGGTCTGCATCCTGCT 
ABCA4-ex03-R-BAMHI ggatccGGAAACCTGCTCTGCTCCTA 
ABCA4-ex09-F-EcoRI gaattcAATCCTCCAGCATGGAGTTG 
ABCA4-ex09-R-BAMHI ggatccCACTGAAGCAAAGCATTCCA 
ABCA4-ex13-F-EcoRI gaattcTGAGTTCCGAGTCACCCTGT 
ABCA4-ex13-R-BAMHI ggatccGTCAGAGCTCCATGCTCTCC 
ABCA4-ex19-F-EcoRI gaattcGGGCCATGTAATTAGGCATT 
ABCA4-ex19-R-BAMHI ggatccCCTCCCCATCAAGAGAATACA 
ABCA4-ex25-F-EcoRI gaattcTGGAGCATCAGTCCTCTGAA 
ABCA4-ex25-R-BAMHI ggatccCTATGCTTGGGTGGGGAAC 
ABCA4-ex29-F-EcoRI gaattcGTGACATGCCATCAGACCAC 
ABCA4-ex29-R-BAMHI ggatccAGTGACCAGCAGAGCAGGAT 
ABCA4-ex30-F-EcoRI gaattcAGAGGAGGAGGAAAGGGTTG 
ABCA4-ex30-R-BAMHI ggatccGGTGCAGGGAGTTTGGTTTA 
ABCA4-ex33_34-F-EcoRI gaattcTTTGTAAAGTGGAGCCATGTTG 
ABCA4-ex33_34-R-BAMHI ggatccGGTAAATTTTTAGCTCCAGAGCAG 
ABCA4-ex35-F-EcoRI gaattcATCCCTCCTCCTGCTGAAAT 
ABCA4-ex35-R-BAMHI ggatccGGTGGTGAGAATCCTCTCAGG 
ABCA4-ex36-F-EcoRI gaattcGTGTAAGGCCTTCCCAAAGC 
ABCA4-ex36-R-BAMHI ggatccCCCTCTTGGTCTGGTCCTTC 
ABCA4-ex37-F-EcoRI gaattcGGGTGGGGTAGGAGGACTA 
ABCA4-ex37-R-BAMHI ggatccACAGCCCAGGTTTTCTGTCA 
ABCA4-ex46_47-F-EcoRI gaattcCTGTCAGCTCATCCTCCACA 
ABCA4-ex46_47-R-BAMHI ggatccGAGCAGCAGGACTCTTCCAA  
ABCA4-ex49-F-EcoRI gaattcTACCAGCAGGGCTGTATGTG 
ABCA4-ex49-R-BAMHI ggatccGGCATATCTGAGCCTTGGAG 
CNGB3-ex9-F-EcoRI gaattcCCATGCTATAAAATGTACTGTCCAGAGGA 
CNGB3-ex9-R-BAMHI ggatccCCTGCCAAATTCCGTCTAAAATGTTGT  
M13-F CGCCAGGGTTTTCCCAGTCACGAC 
M13-R AGCGGATAACAATTTCACACAGGA 
pSPL3bF GAGAAATATCAGCACTTGTG 
pSPL3bR GTACACCGGCATGTGTGGCC 
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SD2 GTGAACTGCACTGTGACAAGC 
SD6 TCTGAGTCACCTGGACAACC 
SA2 ATCTCAGTGGTATTTGTGAGC 
SA4 CACCTGAGGAGTGAATTGGTCG 
Table 5: Primers*, including gene, exon, restriction site, and sequence   
*cc 100 µM, dilution 1:10; company: Metabion. (see Appendix) 
2.4 ORGANISMS AND CELL TYPES  
Strain/Cell line Characteristics Source 
 
E.coli strain DH5α nuclease deficient Inst. of Human Genetics UR 
HEK 293 EBNA human embryonic kidney cells Inst. of Human Genetics UR 
Table 6: Bacteria strains and cell lines 
2.5 PLASMIDS 
Plasmid Size (kb) Resistance Application Source 
 
pGEM-T    3 Ampicillin WT/Mut selection Promega 
pSPL3b    6 Ampicillin Transfection Inst. of Human Genetics UR 
Table 7: Plasmids  
2.6 ENZYMES  
Enzyme Application Company 
 
Go-Taq polymerase (5U/µl) PCR cDNA Promega 
Pfu polymerase (Pyrococcus furiosus) PCR Inst.Human Genetics UR 
Restriction enzymes (EcoRI, BamHI) Plasmid digestion Biolabs 
Taq polymerase (Thermos aquaticus) PCR Inst.Human Genetics UR 
T4-DNA Ligase Ligation Promega 
Trypsin (0,5%) EDTA (0,2%) 1 x in PBS Cell culture PAA 
Table 8: Enzymes  
2.7 KITS 
Kit Application Company 
 
BigDye Terminator v1.1, v3.1 Cycle Seq. Kit Sequencing Applied Biosystems 
RevertAid ™ H First Strand cDNA Synthesis 
Kit 
Reverse transcription Thermoscientific 
NucleoSpin® Gel and PCR Clean Up PCR purification Macherey-Nagel 
NucleoSpin® Plasmid Clean Up 
Plasmid DNA 
purification 
Macherey-Nagel 
pGEM T- Vector System Cloning Promega 
Rneasy Micro Kit RNA isolation Qiagen 
TransIT®-LT1 Transfection reagents Transfection Mirus 
Table 9: Kits 
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2.8 CHEMICALS/SUBSTANCES  
Chemical/Substance Application Company 
 
Agarose Gel electrophoresis Biozym 
Ampicillin Sodium Salt LB-med./plates Carl Roth 
β-Mercaptoethanol RNA isolation Sigma 
Bacto agar LB-ampicillin plates Becton, Dickson & Co. 
Bacto yeast extract LB-ampicillin plates Becton, Dickson & Co. 
Boric acid TBE Merck 
Bromphenol blue Loading buffer Sigma 
Buffer 4 Ligation into pSPL3b Biolabs 
Chloroquin 25mM Transfektion Biomol 
DMEM Cell culture Gibco 
dNTPs PCR Genaxxon Bioscience 
EDTA TBE/cell culture Merck 
Ethanol ≥ 99,8 %; 70% DNA percipitation Carl Roth 
Ethidium bromide Gel electrophoresis AppliChem 
Fetal Calf Serum (FCS) Cell culture Gibco 
Ethylenediaminetetraaceticacid (EDTA) Cell culture AppliChem 
Generuler 1kb Gel electrophoresis Invitrogen 
Glycerin 99,5% Stock perservation Inst.Human Genetics UR 
HiDi Formamide DNA percipitation AppliBiosys 
Instant Sticky-end Ligase Ligation into pSPL3b Biolabs 
Isopropylthio-β-galactoside (IPTG) Blue/white selection AppliChem 
Lysin (Poly-L) Cell culture Sigma 
PBS 10x pH 7.4 Cell culture Gibco 
Penicillin/Streptomycin Antibiotics Gibco 
Peptone from casein, tryptin digested LB-med./plates Carl Roth 
Sodiumacetate  3M DNA percipitation Merck 
Sodiumchloride LB-med./plates VWR 
Tris TBE VWR  
X-Gal Blue/white selection Sigma 
Xylencyanol blue Loading buffer Sigma 
Table 10: Chemicals/Substances 
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2.9 SOLUTIONS/BUFFERS/MEDIUM 
Solutions/Buffer Composition Amount Application 
 
Agarose gel TBE 1x 
Agarose 
 
1-2% 
Gel electrophoresis 
 
 
Buffer 4 pH 7.9 
 
 
50 mM K-acetate 
20 mM Tris-acetate 
10 mM Mg-acetate 
1mM DTT 
  
 
Restriction 
digestion 
dNTPs (cc 100 mM) dATP 
dTTP 
dGTP 
dCTP 
12,5 µl in 950 µl dH₂O 
12,5 µl in 950 µl dH₂O 
12,5 µl in 950 µl dH₂O 
12,5 µl in 950 µl dH₂O 
PCR 
Instant Sticky-end Ligase Gylcerol 
PEG-6000 
Proprietary Information 
Tris-HCL 
20% 
13.6% 
5% 
1.5% 
pSPL3 Ligation 
Poly-L-Lysin Dil 1:50 with 1x PBS   Cell culture 
TBE 5x pH 8,0 Tris (0.44 M) 
Boric acid (0.44 M) 
EDTA (0.5 M) pH 8 
dH₂O 
216 g in 4 L 
110 g in 4 L 
80 ml in 4L 
4 L 
Gel electrophoresis 
Xylencyanol blue Xylencyanol 
Glyerin 
dH₂O 
0,05 g 
20 ml 
Ad 50 ml 
Loading buffer gel 
electrophoresis 
 
Table 11: Solutions/Buffers 
 
Medium Composition Amount Application 
 
HEK 293 EBNA 
(DMEM+) 
DMEM (glucose 4,5g/L) 
FCS 
Pen/Strep 
500 ml 
10% 
1% 
Cell culture 
LB Medium Pepton 
Yeast extract 
NaCl 
dH₂O 
Ampicillin (cc 100 μg/ml) 
10g 
5g 
10g 
1L 
1 ml 
Bacteria growth and 
selection 
LB Plates + Agar 15g Cloning 
SOC Pepton (2%) 
Yeast extract (o.5%) 
NaCl (10mM) 
KCl (2.5mM) 
dH₂O 
pH 7.0 autoclave 
20g 
5g 
0.5g 
0.186g 
1L 
E. coli DH5α recovery 
Table 12: Medium 
 
 
24 
 
2.10 LABORATORY MATERIAL 
Material Application Company 
 
6-well plates Transfection Corning, Inc. 
96-well plates Sequencing VWR 
Cassette Gel electrophoresis  Serva 
Cell culture dishes Cell culture Sarstedt 
Cell scraper RNA isolation Orange Scientific 
Combs Gel electrophoresis Serva 
Disposable Pasteur pipettes 3 ml Gel electrophoresis VWR 
Eppendorf cups 0.5ml/1.5ml/2.0 ml Miscellaneous Sarstedt 
Falcon® tubes 15 ml/50 ml Miscellaneous Sarstedt 
Glass pipettes Miscellaneous Brand 
Nitrile gloves (blue) Miscellaneous VWR 
Nitrile gloves (green) Miscellaneous KIMTECH 
Needles 0.6/30 mm RNA isolation Becton, Dickson & Co. 
PCR cups Miscellaneous Biozym 
Petri dishes – bacteria culture Cloning Sarstedt 
Pipette tips 10 µl/100µl, 1000µl Miscellaneous VWR 
Scalpel Gel purification Feather 
Syringe Omnifix 10 RNA isolation Braun 
Table 13: Laboratory material 
2.11 INSTRUMENTS AND APPLIANCES 
 
Instrument/appliance Company 
 
Autoclave V-150 Systec GmbH 
Bacteria hood ThermoScientific 
Cell culture hood BDK GmbH 
Centrifuge (mikro) Qualitron 
Centrifuge 5415R Eppendorf 
Centrifuge Multifuge 3L ThermoScientific 
Centrifuge Megafuge 1.0R ThermoScientific 
Centrifuge 5810 eppendorf 
Dark hood DH 30/32 Biostep 
Gel electrophoresis voltage boxes Serva 
Gel electrophoresis chambers Blue Marine 200 Serva 
Scepter®Hand-held automatic cell counter Millipore 
Ice machine AF 100 Scotsman 
Incubator 37°C Memmert 
Incubator shaker Certomat® R B.Braun Biotech 
Microwave Daewood 
Millipak® Water System Millipore 
Multichanel pipette Abimed 
Multipipette® Plus eppendorf 
ND1000 Spectrophotometer NanoDrop® 
Pump - cell culture hood eppendorf 
Pipettes10µl/100µl/1000µl Applied Biosystems 
3130x1 Genetic Sequenzer Biometra 
Thermocycler Biometra 
Thermocycler T3 eppendorf 
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Thermomixer compact eppendorf 
Vortex 2 Genie ScientificIndustries 
Water bath Aqualine Lauda 
Water distiller 2012 GFL 
Table 14: Instruments and Appliances 
2.12 SOFTWARE 
 
Software Application Provider 
 
Argus 3.0 Gel documentation Biostep Jahnsdorf GmbH 
ApE Check for restriction sites 
http://biologylabs.utah.edu/jorgensen/
wayned/ape/ 
Chromas Sequence analysis www.technelysium.com.au 
ExPASy Bioinformatics 
Resource Portal 
Protein translation http://web.expasy.org/translate/ 
Gene Splice Finder 
Splice site predictor  
(scale 0-15) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
Human Splicing Finder 
Splice site predictor 
 (scale 0-100) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
Interactive Biosoftware  Protein translation 
http://www.interactive-
biosoftware.com/ 
Neural Network 
Splice site predictor  
(scale 0-1) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
MaxEntScan 
Splice site predictor  
(scale 0-12) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
Primer 3 Primer design http://primer3.ut.ee/ 
Splice Site Finder 
Splice site predictor 
 (scale 0-100) 
Accessed through Alamut platform 
(Interactive Biosoftware, Rouen, 
France) 
USCS Genome Browser Sequence mapping  http://genome.ucsc.edu/ 
Table 15: Software 
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3 METHODS 
3.1 POLYMERASE CHAIN REACTION (PCR) 
Patient DNA was extracted from peripheral blood and diluted to a concentration of 25 
ng/μl and the regions of interest PCR amplified. Unless otherwise specified, the polymerase 
used was a 7:1 ratio of Taq:Pfu (Thermus aquaticus:Pyrococcus furiosus). The following tables 
show the protocol implemented for PCR reactions in this work. 
 
Reagent Volume 
 
H₂O 16.0 µl 
MgCl₂ (15 mM)   2.5 µl 
dNTP                     2.0 µl 
Forward primer   1.0 µl 
Reverse primer  1.0 µl 
Taq-Pfu  0.5 µl 
DNA template  2.0 µl 
Table 16: PCR Protocol 
 
Step Temperature Time 
 
Initial 
denaturation 
       94 ° C 3 min 
Denaturation        94 ° C 30 s* 
Annealing        57 ° C 30 s* 
Elongation        72 ° C 2 min* 
Final elongation 72  C 5 min 
Table 17: PCR Thermocycler programme 
*33 cycles 
3.2 AGAROSE GEL ELECTROPHORESIS AND DOCUMENTATION  
This method of separation relies on an electrical current to move negatively charged 
DNA molecules towards the positively-charged anode. Smaller molecules can pass more 
readily through the gel matrix than larger ones and enables separation according to molecular 
size.42 The PCR amplified DNA was separated on a 1% agarose gel at 200 V, unless otherwise 
stated. Agarose was dissolved in 1x TBE buffer by heating the mixture to near-boiling point in 
a microwave. After cooling, 1-2 drops of ethidium bromide were added to enable fluorescence 
of the DNA fragments under UV light. The mixture was poured into a cast fitted with individual 
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combs to form the wells. Once hardened, the gel cast was placed into an electrophoresis tank 
containing 1x TBE running buffer. 4 μl loading buffer and 10 μl PCR product were pipetted 
into each well. A DNA ladder (GeneRuler) allowed for estimation of the molecular size (kb) of 
the DNA fragments. Once the fragments were separated adequately, they were visualized using 
UV light and documented with the Argus 3.0 software. 
3.3 GEL PURIFICATION 
DNA extraction from the agarose gel was done using the NucleoSpin® Gel and PCR 
Clean Up kit, which also removed contaminants such as excess nucleotides, primers, enzymes, 
salts and dyes (Macherey-Nagel manual 2012). The following modifications were made to the 
protocol: 
Step 4: centrifuge for 2 min leave open to dry for 3 min 
Step 5: eluted with 25μl Millipore water 
3.4 SPECTROPHOTOMETRY   
The NanoDrop ND1000 Spectrophotometer measures nucleic acid samples (V=1 μl) on 
a spectrum of 220nm-750 nm up to concentrations of 3700 ng/μl (Nanodrop1000). The sample 
concentration given in ng/μl is based on an absorbance of 260 nm. Sample intensities along 
with blank intensities (deionized water) are used to calculate the sample absorbance. 
3.5 CLONING   
 Ligation 
The Taq polymerase creates an adenine overhang on the 3′ end of the amplified PCR 
fragment, which can then be ligated into the linearized pGEM® T vector due to the 
complementary thymidine overhang on both 3′ ends of the insertion site (Promega manual, 
2010). The protocol used for ligation is shown in the table below:  
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Reagent Volume 
 
pGEM®T Vector 0.5 µl 
T4 DNA Ligase 1.0 µl 
2X Rapid Ligation Buffer 5.0 µl 
Insert 3.5 µl 
Table 18: Ligation protocol (incubation at 4° C overnight) 
 Transformation 
After approximately 18 h, the ligation product was transformed in competent E. coli 
DM5α cells. The bacteria (stored at – 80°C) were thawed slightly in an ice bath before adding 
5 μl of the ligation preparation. A reaction time of 30 min on ice was followed by a heat shock 
phase of 40 s at 42°C and a 120s recovery time on ice. 900 μl of SOC medium was added and 
the cells were placed in the incubator shaker Certomat R for 3 h at 37°C and 165 rpm. Prior to 
plating out 200 μl of the transformed cell mixture, 50 μl X-gal (40 mg/ μl) and 10 μl 100 mM 
IPTG were added to the LB + ampicillin plates for the purpose of blue-white screening of 
positive clones.  The pGEM® T vector contains promoters on either side of a multiple cloning 
region within the α-peptide coding region of the β-galactosidase. Proper insertion of the DNA 
fragment into the vector disrupts the reading of α-peptide, thus preventing functional β-
galactosidase from being formed and resulting in white (+) colonies (Promega manual, 2010). 
The plates were incubated for 18 h at 37° C. 
 Screening positive clones 
Positive colonies were further screened for correct insertion and size via colony PCR. 
Positive colonies were picked and incubated for 60 min at 37° C in 20 μl LB+ampicillin broth. 
The colony PCR was performed using M-13 forward and reverse primers (Table 5). Gel 
electrophoresis on a 1% agarose gel and UV documentation were used to separate the DNA 
fragments and assess the size. From those colonies showing correct insertion and appropriate 
fragment size, four to six were selected for inoculation. 5 μl of the 20 μl inoculated 
LB+ampicillin medium was added to 5 ml of LB+ampicillin broth and incubated in the 
Certomat R for 18 h at 37° C and 165 rpm. 
3.6 PLASMID DNA PURIFICATION 
The cultured medium was centrifuged at 4000 rpm for 5 min in order to pellet the 
bacteria cells. Purification was performed using the NucleoSpin® Plasmid kit (Macherey-Nagel 
manual, 2010). The cell pellet was re-suspended in a buffer before liberating the plasmid DNA 
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from the host cells via SDS/alkaline lysis. The lysate was then neutralized in order to allow it 
to bind to the silica membrane of the column. Unwanted debris can be pelleted via 
centrifugation before loading the supernatant onto the column. The Macherey-Nagel protocol 
for plasmid DNA preparation (2010) was adhered to, apart from the following modifications: 
 
Step 1: centrifugation 5 min at 4000 rpm 
Step 4: discard overflow and dry an additional 60 s at 11 000 g 
Step 5: omitted Buffer AW 
Step 6: centrifuge 3 min, leave open to dry 3 min 
Step 7: elute with 30 μl purified water 
 
The concentration of the plasmid DNA was measured using the NanoDrop ND1000 
spectrophotometer. 
3.7 SEQUENCING  
The plasmid DNA was diluted to 25 ng/µl and 2 µl was used as a template for the 
sequencing reaction. For the PCR, the BigDye Terminator v1.1.v3.1 Cycle Sequencing Kit from 
Applied Biosystems was used, according to following protocol: 
 
 
Reagent Volume 
 
Big Dye Reaction mix 0.3 µl 
5x Buffer 2.0 µl 
Primer 1.0 µl 
H₂O 4.7 µl 
DNA 2.0 µl 
Table 19: Sequencing protocol 
Step Temperature 
°C 
Time Cycle 
 
Initial 
denaturation 
94 2 min  
Denaturation 94 30s  
Annealing 57 30s 30 
Elongation 72 3 min  
Final 
elongation 
72 5 min  
Table 20: Amplification conditions 
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 Sequencing PCR products directly 
When sequencing PCR product directly, an initial step to remove excess 5′ phosphates 
and dNTPs was carried out using Antarctic Alkaline Phosphatase and Exonuclease I 
respectively. 
 
Reagent Volume 
Exo 0.10 µl 
AAP 0.25 µl 
H₂O 3.65 µl 
PCR Product 1.00 µl 
Table 21: Exo/AAP digestion 
After incubating for 15 min at 37°C and a further 15 min at 80°C, the following was added:  
 
Reagent Volume 
Big Dye Reaction mix  0.30 µl 
5x Buffer 1.85 µl 
Primer 1.00 µl 
H₂O 1.85 µl 
Table 22: Sequencing protocol following Exo/AAP digestion 
Amplification conditions (Table 20). 
 
The reaction products for sequencing were purified by adding 2 µl NaAc and 50 µl 100% 
ethanol and vortexing briefly before centrifuging for 30 min at 4°C and 4000 rpm. The 
supernatant was immediately discarded and the pellet centrifuged again for 2 min at 800 rpm. 
Next, 70 µl 70% ethanol was added and centrifuged for another 30 min at 4°C and 4000 rpm. 
After discarding the supernatant and centrifuging for 2 min at 800 rpm, the pellet was dried at 
RT for 15 min, re-suspended in 15 µl HiDi Formamide and pipetted into the 96 well plate for 
sequencing (Abi3130x1 Genetic Analyzer). Sequences were analyzed with Chromas 2. 
3.8 EXON TRAPPING 
This study utilized the pSPL3b expression vector to examine splicing behavior (Fig. 
10). The vector consists of two exons flanking an intron containing a multiple cloning site, into 
which the fragment of interest can be inserted. The vector was linealized with restriction 
enzymes identical to those used to digest the construct. The SV40 promoter region, located 
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upsteam from the cloning sites, is used to drive transcription in eukaryotic cells, with the ori 
(replication origin) and amp (ampicillin resistance) sites being necessary for replication and 
selection in E. coli.58 As shown in Fig. 10, the specific vector primers SD6 and SA4 (Table 5) 
were used for sequencing. Each insert consisted of one, in some cases two, exons with flanking 
intronic sequence of varying size (Table 4). 
 
 
 
 
Figure 10: pSPL3b vector 
 
 
BamHI     G/GATCC 
                  CCTAG/G 
EcoR1      G/AATTC 
                 CTTAA/G         
                                
Figure 11 Restriction enzymes BamH1 and Eco R1 
 
 
 
SV40 origin and promoter SV40 polyadenylation site 
amp 
ori 
E E
BamHI EcoRI 
SD6 
AS 
1st DS 
SA4 
2nd DS 
ABCA4 
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 Preparation of pSPL3b vector 
Reagent Amount 
 
pSPL3b vector plasmid 
DNA stock 
2.0 µl 
EcoR1 0.5 µl 
BamH1 0.5 µl 
Buffer 4 3.0 µl 
H₂O                24.0 µl 
Temperature                37°C 
Time  Overnight 
Table 23: Vector preparation protocol – linearization 
 
The reaction was set up in fourfold. Digested plasmid was loaded on a 1% agarose gel, the band 
containing the linearized vector was cut out, purified using the NucleoSpin® Gel and PCR 
Clean Up kit (Macherey-Nagel manual, 2012) according to protocol, and eluded with 50 µl 
Millipore H₂O. All four were pooled together (VTotal = 200 µl), and 5 µl from the pooled vector 
samples was loaded onto a gel to estimate the concentration. To ensure proper linearization, 
transformation of competent E. coli DM5α was performed according to the following protocol: 
 
Reagent Amount 
 
pSPL3b vector 1 µl 
Sticky end master mix 5 µl 
H₂O                   24 µl 
Table 24: Vector preparation protocol – control transformation 
 
No colonies appeared on the LB + ampicillin plates indicating the vector had been completely 
linearized. 
 Digestion of Plasmid DNA 
A double restriction enzyme digestion with EcoRI and BamHI was carried out to first 
excise the constructs from the pGEM vector for subsequent cloning in pSPL3b.  For plasmids 
of a concentration of 250-500 ng/ µl the following protocol was used: 
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Reagent Volume 
 
Plasmid 10.0 µl 
EcoRI  0.5 µl 
BamHI  0.5 µl 
Buffer 4 3.0 µl 
H₂O                 16.0 µl 
Temperature 37°C 
Time Overnight 
Table 25: Restriction enzyme digestion protocol   
Up to 23 µl of digested plasmid was used for plasmids with very low concentrations. 
The digested products were fragmented on a 1% agarose gel and purified using the  
NucleoSpin® Gel and PCR Clean Up kit (Macherey-Nagel manual, 2012)  
 Ligating into pSPSL3b 
4 µl of the purified construct was ligated into 1 µl pSPL3b splicing vector in 5 µl of 
Instant Sticky-end Ligase Master Mix, transformed in E. coli DH5α competent cells (see 3.5.2), 
and 200 µl plated out. Overnight culture in 5 ml LB+Amp was made from 3 colonies per plate 
and the plasmid purified. In order to confirm proper insertion, the digestion (Table 25) was 
repeated with a shorter incubation time (2h), and the product fragmented on a 2% agarose gel. 
All clones selected for transfection were sequenced before use to verify correct clone integrity. 
A colony stock of pSPL3b + construct was preserved in a glycerin solution (130 µl stock in 870 
µl 99.5 % glycerin) and stored at -80°C. 
3.9 TRANSFECTION OF HEK 293 EBNA CELLS 
DMEM+ medium refers to Dulbecco`s Modified Eagle Medium supplemented with 
FCS and pen/strep (Tables 10 & 12). DMEM- refers to medium without additives. In order to 
enable cell adherence, thus increasing transfection efficiency, the culture dishes were coated 
with poly-L-lysine. For this purpose, 6-well plates were incubated at 37°C overnight with 2 ml 
of poly-L-lysine solution (1:1 PBS1x: poly-L-lysin+pen-strep). 
 
Substance Amount 
 
Poly-L-Lysin 1000  µl 
Pen-Strep   500 µl 
from above solution    50 µl 
in PBS 1x     50 µl 
Table 26: Poly-L-Lysine solution 
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The solution was removed, and the wells rinsed with 1xPBS before sowing. 
 Splitting and sowing HEK 293 EBNA cells 
Prior to beginning, a thorough disinfection of the working space with 70% ethanol, 
including all instruments under the cell culture hood, was carried out. The DMEM+ medium 
and trypsin were warmed in a 37°C water bath for 30 minutes. Cell growth and confluency were 
assessed under the microscope before splitting, which was generally done at a ratio of 1:5. 
The old medium was removed with a glass Pasteur pipette, then 5 ml of 1x PBS carefully 
pipetted against the petri dish wall, redrawn, and 5 ml 0,5M EDTA+1xPBS added (incubation: 
7 min at 37°C). The 5 ml 0,5M EDTA+1xPBS was removed and 3 ml of 2x trypsin added 
(incubation: 3 min at 37°C). 7 ml DMEM+ was added to the trypsin to re-suspend the cells. To 
do so, the medium was repeatedly pipetted up and down while turning the dish, until all cells 
were in suspension. This cell solution was then transferred to a 15 ml Falcon® tube and 
centrifuged for 3 min at 1500 rpm. The supernatant was removed, the pellet re-dissolved in 10 
ml of fresh DMEM+ medium, of which 2 ml was sowed in 8 ml of fresh DMEM+ medium 
(splitting 1:5). 
 Transfection reaction 
For transfection, confluency should ideally be 50-70%. 18 h prior to transfection, the 
HEK 293 EBNA cells were split and sown at 1 000 000 cells/ well in 6 well plates. The 
transfection was performed with TransIT®-LT1 Transfection Reagent (Mirus). For a 6 well 
plate, 16 µl of chloroquine was added to 16 ml DMEM+ medium. The old DMEM+ medium 
was removed from the wells and 2.5 ml of the chloroquine-enriched DMEM+ added 
(incubation: max. 90 min at 37°C).  After 60 min, two Eppendorf cups per plasmid were 
prepared:  
 
Cup 1: 250 µl DMEM-    +   3 µg plasmid 
Cup 2: 250 µl DMEM -   +   6 µl TransIT®-LT1 transfection reagent  
                                        (1 µg plasmid: 2 µl TransIT®-LT1 Transfection reagent).  
 
Both cups were vortexed and incubated for five min at room temperature before adding the 
contents of cup 1 to cup 2 and incubating for a further 25 min at room temperature.   
After a 90 min total incubation time, the chloroquine-enriched DMEM+ was replaced 
with 2 ml fresh DMEM+ before adding 500 µl of the Mirus/construct. To avoid a rapid change 
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in pH, the transfection mix must be added very carefully while gently shaking the plate back 
and forth. 
 Harvesting of HEK 293 EBNA cells 
The cells were incubated post-transfection for 72 h and harvested as follows: the 
DMEM+ medium was discarded and each well washed with 2 ml 1x PBS. A solution of 5 ml 
RLT Buffer (RNeasy Mini Kit, Qiagen) and 50 µl β-Mercaptoethanol was prepared. After 
taking up the 2 ml 1x PBS, 350 µl of the RLT Buffer/β-Mercaptoethanol was added to each 
well. Using a sterile cell scraper, the wells were scraped to loosen the cells, and the cell-
containing liquid was transferred to a 2ml tube. This step was done twice to increase the yield 
(VTotal = ca. 700 µl). 
3.10 RNA ISOLATION 
Total cytoplasmic RNA extraction from the HEK 293 EBNA cells was done using 
RNeasy Mini Kit (Qiagen). In order to shear the DNA, the 700 µl cell suspension was aspirated 
and flushed out of a syringe seven times. Subsequently, 700 µl 70% ethanol was added, 
homogenized and pipetted up and down several times. The cell suspension was loaded onto the 
column (Vmax 700 µl), centrifuged for 15 s at 10 000 rpm, the supernatant discarded, and this 
step repeated with the remaining 700 µl. 
The column was washed with 350 µl RW-1 buffer and centrifuged for 15 s at 10 000 
rpm before adding a solution of 10 µlDNase + 70 µlRDD buffer, incubated for 15 min at room 
temperature and washed as follows:  
 
Wash step Buffer Volume  Centrifuge 
time  
(10 000 rpm) 
1 RW-1 350 µl 15 s 
2 RPE 500 µl 15s 
3 RPE 500 µl 2 min 
Table 27: RNA isolation: washing steps 
 
After the final washing step, the column was placed in a clean 2 ml collection tube and 
centrifuged for 2 min at maximum speed. The RNA was eluted in 30 µl RNase free water by 
centrifuging 60 s at 9000 rpm, the concentration measured using the ND1000 
Spectrophotometer, and the samples stored at -80°C. 
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3.11 CDNA SYNTHESIS VIA REVERSE TRANSCRIPTASE PCR 
Using the RevertAid ™ H First Strand cDNA Synthesis Kit and Random Hexamer 
primer, the RNA isolated from the HEK 293 EBNA cells was reverse transcribed into 
complementary DNA (cDNA) for further analyses as follows: 
 
Step Reagent Volume/Amount 
 
1 
Random 
Hexamer Primer 
1.0 µl 
  RNA 5.0 µg 
  
H₂O, nuclease-
free 
12.5 µl 
2 Incubate   5 min 70°C 
3 Place on ice  
4 5 x Buffer 4.0 µl 
 NTPs 2.0 µl 
 
Reverse 
Transcriptase 
0.5 µl 
Table 28: cDNA synthesis protocol 
 
Temperature Time 
 
25 ° C 10 min 
42 ° C  60 min 
70 ° C 10 min 
Table 29: cDNA synthesis Thermocycler programme 
Storage of cDNA -20°C 
3.12 CDNA PCR 
To characterize and carry out further analysis of the splicing behavior in the transfected 
HEK 293 EBNA cells, a PCR using the synthesized cDNA was performed (Table 30) according 
to the method outlined in 3.1.  Separating the cDNA fragments on a 2 % agarose gel via 
electrophoresis (3.2) enabled an initial visual analysis to compare product sizes to the calculated 
estimations, based on an assumption of correct splicing activity in the normal allele. 
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Reagent Volume 
 
H₂O 14.9 µl 
GoTaq buffer 5.0 µl 
dNTP 2.0 µl 
SD 6   1.0 µl 
SA 4 1.0 µl 
Go-Taq (cc 5U/ µl) 0.1 µl 
Master Mix 24.0 µl 
DNA Template 1.0 µl 
Table 30: cDNA PCR Protocol 
Amplification conditions: (see 3.1)  
 
If correct splicing occurred, we expected to observe the phenomenon depicted by Product B 
(Fig. 12). However, should a splice site be diminished in strength due to a mutation, the region 
of interest may become spliced out entirely, as is shown in Product A. Alternatively, a cryptic 
site may be used, resulting in a product size deviating from the transcript of the normal allele, 
as seen in Product C.  
 
 
Figure 12: Possible splicing scenarios, depending on variant effect on splicing 
In order to verify the nature of each band, products were cloned and/or sequenced according 
to the methods described in 3.5 through 3.7.
Product A Product B Product C 
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4 RESULTS 
Prior to beginning this dissertation, the coding region including the immediate flanking 
intronic sequences of ABCA4, CNGB3 and ELOVL4 in patients clinically diagnosed with 
Stargardt disease or cone-rod dystrophy had been analyzed at the Institute for Human Genetics 
at the University of Regensburg, Germany.  Of the total 152 unique variants found (Table 1), 
those with a minor allele frequency of <1% were subjected to further in silico testing using five 
bioinformatics prediction programmes (Table 15) to assess the spliceogenic potential. The 
purpose of the dissertation was to perform functional analyses of splicing behaviour in variants 
(N=21) that that had been predicted in silico to affect splicing. 
4.1 RESULTS OF BIOINFORMATIC PREDICTIONS OF VARIANTS’ EFFECT ON 
SPLICING 
Pat. 
ID  
(Medistar) 
Ex
ID 
Variant Nearest 
canonical 
splice site 
Predict-
ion for 
SSF 
[≥70] 
MaxEnt 
[≥0] 
NNSplice 
[≥0.4] 
Genesplicer 
[≥0] 
HSF 
[≥60] 
18962 
 
A 
 
c.67-1G>C 
 
Exon 2 - 
c.67 (A) 
 
c.67 
(A) 
 
95.2⇒  
lost 
 
10.87 ⇒  
 lost 
 
0.99 ⇒ 
 lost 
 
12.03 ⇒ 
 lost 
 
92.11 ⇒ 
 lost 
 
16843 
 
G 
 
c.67-2A>G  
 
Exon 2 - 
c.67 (A) 
 
c.67 
(A) 
 
95.2⇒  
lost 
 
 10.87 ⇒  
 lost 
 
0.99 ⇒ 
 lost 
 
12.03 ⇒ 
 lost 
 
92.11 ⇒ 
lost 
 
17412 
 
U 
 
c.160+2T>C     
 
Exon 2- 
c.160  
(D) 
 
c.160 
(D) 
 
81.30 ⇒  
78.5   
(-3.4%) 
 
6.12 ⇒  
lost 
 
0.94 ⇒  
lost 
 
No 
prediction 
86.00 ⇒
 lost 
 
17716 
 
H 
 
c.179C>T 
 
Intron2 - 
c.161-1 
 
c.177  
(D) 
 
gained⇒    
77.92 
 
gained ⇒ 
5.22  
 
gained ⇒  
0.59 
 
gained⇒ 
4.39 
 
No 
predict-
ion 
15485 
 
F* 
 
CNGB3 
c.991-3T>G  
 
Intron 8 - 
c.991 (A) 
 
c.991-2 
(A) 
 
gained ⇒  
85.58 
 
gained  ⇒  
9.77 
 
gained  ⇒ 
0.99 
 
gained  ⇒ 
1.79 
 
gained  
⇒  
81.99 
 
15485 
 
 
 CNGB3 
c.991-3T>G  
 
Exon 9 - 
c.991 (A) 
 
c.991  
(A) 
 
81.65 ⇒ 
77.00  
 
7.60 ⇒  
 lost 
 
0.94 ⇒   
lost 
 
no 
prediction 
 
82.86 ⇒
 80.25  
 
15282 
 
I 
 
c.1239+1G>
C 
 
Exon 9 - 
c.1239 
(D) 
 
c.1239 
(D) 
 
81.75 ⇒ lost 
 
5.55 ⇒  
lost 
 
0.61 ⇒  
lost 
 
6.20 ⇒  
lost 
 
85.84 ⇒
 lost 
 
20364 
 
J 
 
c.1937+1G>
A 
 
Exon 13 
- c.1937 
(D) 
c.1937 
(D) 
 
no 
prediction 
 
7.90 ⇒ 
 lost 
 
0.83 ⇒  
lost 
 
4.22 ⇒  
lost 
 
81.10 ⇒
 lost 
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21529 
 
K 
 
c.1819G>A 
 
Exon 13 
c.1761(A
) 
 
c.1837 
(A) 
 
No change 7.70   ⇒ 
6.36   
(-17.4%) 
 
0.69 ⇒ 
0.65     
(-5.8%) 
 
2.68 ⇒  
2.09 
(-21.8%) 
 
no 
predict-
ion 
 
15023 
 
L 
 
c.2894A>G 
 
Exon 19 
c.2744 
(A) 
c.2918 
(D) 
c.2895 
(A) 
 
gained ⇒  
75.24 
 
gained ⇒ 
4.35 
 
no 
prediction 
 
no 
prediction 
 
no 
predict-
ion 
 
16178 
 
M 
 
c.3808G>T 
 
Exon 25 
- c.3813 
(D) 
 
Exon 25 
- c.3813 
(D) 
 
gained ⇒ 
73.14 
 
gained ⇒ 
4.35 
 
- - - 
15286 
 
N 
 
c.4352+1G>
A 
 
Intron 28 
- c.4352 
(D) 
Exon 29 
- c.4352 
(D) 
 
73.65 ⇒  
lost 
 
10.27 ⇒  
lost 
 
0.98 ⇒  
lost 
 
4.67⇒  
lost 
 
no 
predict-
ion 
 
14686 
 
O 
 
c.4354G>T 
 
Exon 30 
- c.4353 
(A) 
 
c.4353-1 
(D) 
 
no 
prediction 
 
gained ⇒ 
4.45 
 
gained ⇒ 
0.56 
 
no 
prediction 
 
gained 
⇒ 75.25 
 
16827 
 
P 
 
c.4457C>T 
 
Exon 30 
- c.4353 
(A) 
 
c.4467 
(A) 
 
84.51 ⇒  
87.79  
 
9.24 ⇒  
9.79 
 
0.91 ⇒  
0.93 
 
6.51 ⇒  
7.23 
 
89.64 ⇒
 90.35                  
 
21066 
 
B c.4773+3A>
G  
 
Exon 33 
- c.4773 
 (D) 
 
c.4773 
(D) 
 
77.81 ⇒  
73.45  
(-5.6%) 
 
7.48 ⇒  
3.14  
(-58.1%) 
 
0.96 ⇒  
lost 
 
1.99 ⇒  
lost 
 
86.04 ⇒
 74.99   
 
15977 
 
C c.4919G>A  
 
Exon 35 
- c.4849 
(A) 
 
c.4921 
(A) 
 
gained ⇒ 
81.21 
 
gained ⇒ 
5.78 
 
no 
prediction 
 
gained ⇒ 
1.97 
 
gained 
⇒ 88.40 
 
17002 
 
D c.5018+2>C  
 
Exon 35 
- c.5018 
(D) 
 
c.5018 
(D) 
 
72.34 ⇒  
lost 
 
5.32 ⇒  lost 
 
0.87 ⇒  
lost 
 
1.11 ⇒   
lost 
 
81.15 ⇒  
lost 
 
16272 
 
Q 
 
c.5196+1G>
A 
 
Intron 36 
c.5196+4 
(D) 
 
Exon 36 
- c.5196 
(A) 
 
77.87 ⇒  
lost 
 
10.44 ⇒  
lost 
 
0.98 ⇒  
lost 
 
6.49 ⇒  
lost 
 
83.28 ⇒
lost 
 
17575 
 
R 
 
c.5189G>A 
 
Intron 36 
c.5196 
(D) 
 
Exon 36 
- c.5191 
(A) 
 
gained ⇒ 78.
81 
 
gained ⇒ 6.6
6 
 
no 
prediction 
 
gained ⇒  
3.49 
 
gained 
⇒  
82.96 
 
20882 
 
 
 
 
 
 
S 
 
c.5312+1G>
A 
 
Exon 37 
- c.5312 
(D) 
 
c.5312 
(D) 
 
81.13 ⇒  
lost 
 
8.84 ⇒ lost 
 
     0.99 ⇒   
      lost 
 
    2.22 ⇒   
    lost 
 
90.99 ⇒
 lost 
 
 
17002 
 
 
 
E 
 
 
c.6386+2C>
G  
 
 
Exon 46 
- c.6386 
(D) 
 
  
c.6386 
   (D) 
 
 
91.79 ⇒ lost 
 
- 
 
- 
 
- 
 
- 
16518 
 
T 
 
c.6732G>A 
 
Exon 48 
- c.6730 
(A) 
 
c.6730-1  
(D) 
 
gained  ⇒ 73
.31 
 
  gained  
⇒ 5.39 
 
gained 
⇒ 0.71 
 
no  
prediction 
 
75.74 ⇒
  
76.90  
(+1.5%) 
 
Table 31: Alamut predictions for ABCA4 (N=20) and CNGB3* (N=1) variants investigated in this study, grouped 
according to exon in ascending order 
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Variants completed during this doctoral dissertation are highlighted in bold grey (far left column: Patient ID); the 
remaining were completed in a subsequent study (Baier, 2014)89. 
A: acceptor site; D: donor site; SSF: Splice Site Finder; MaxEnt: Maximum Entropy Scan; NNsplice: Neural Network 
Splice; GeneSplicer: Gene splicer; HSF: Human Splicing finder (Table 3) 
In vitro investigations in this study relied on the exon trapping method using the pSPL3b 
vector. Following replication and selection in E. coli, one construct containing the normal allele 
and another containing the mutation were inserted into the vector. The plasmids were 
transfected in transient cells, the RNA isolated, reverse transcribed, and RT-PCR amplified 
using the vector primers (Table 5). The cDNA products were separated via electrophoresis and 
their sizes compared to the calculated estimations based on an assumption of correct splicing 
activity in the normal allele. The products were subsequently cloned and/or sequenced to verify 
the nature of each band. Several were also investigated via fragment analysis in a later project 
carried out by Maria Baier, 89 and are cited as such. 
4.2 CANONICAL SITE VARIANTS 
 In vitro splicing effect of the ABCA4 c.5312+1G>A variant 
All five bioinformatics tools foresaw a total loss of regular donor site for this guanine 
to adenine change in the highly conserved first base of the splicing donor site. 
 
 
Figure 13: Schematic representation of exon 37, position of ABCA4 variant c.5312+1G>A, and predicted effect of loss 
of donor site 
 
As can be seen in the gel electrophoresis documentation (Fig.14), amplification of the cDNA 
transcribed from the normal allele sequence using primers specific to the artificial exons in the 
pSPL3 vector produced a correctly spliced product (310 bp). The sequence containing the 
variant resulted in a product where the construct had been completely spliced out (194 bp; 
c.5197_5312del; p.Asn1734Glyfs*14), indicating that the splice sequences of internal exons 
had been used.  The use of cryptic sites within the pSPL3b vector is a common problem seen 
in the exon-trapping method, 58, 59 which is why it is important to include the normal allele as a 
Legend 
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Donor site 
Acceptor site 
Loss of site 
41 
 
negative control. Because this nucleotide change is at a canonical splice site, it is not surprising 
that the in vitro results concurred with the in silico predictions for total loss of donor site. 
 
 
 
Figure 14: Above: cDNA gel electrophoresis of ABCA4 variant c.5312+1G>A transcribed from wild-type and mutant 
sequence *indicates correctly spliced reference sequence Below: schematic representation of gel electrophoresis 
 In vitro splicing effect of the ABCA4 c.5018+2T>C variant 
This thymine to cytosine change at the second base of the splicing donor site was 
predicted by all five in silico tools to lead to a complete loss of regular donor site. 
 
 
 
Figure 15: Schematic representation of exon 35, position of ABCA4 variant c.5018+2T>C, and predicted effect of loss 
of donor site 
 
In vitro results of the amplification of the cDNA containing the normal allele sequence showed 
a correctly spliced product (364 bp) in this clone (Fig.16). In addition, a smaller band is present 
WT                     Mut 
c.5312+1G>A 
310 bp 
194 bp 
pSPL3b exon 1 pSPL3b exon 2 
194 bp 
pSPL3b exon 1 pSPL3b exon 2 
*310 bp 
ABCA4 exon 37 
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with vector-only sequence (194 bp; p.Val1617Alafs*113), indicating that even in normal allele 
sequence some constructs will excise this exon. Amplification of the cDNA transcribed from 
the variant sequence resulted in several products. The largest product (538 bp) arose due to the 
loss of the donor site of exon 35 of ABCA4, and consequently included intron 35 and pSPL3b 
sequence up to the next donor site in the vector. The strongest band visible on the gel (194 bp) 
contained vector-only sequence. 
 
 
 
Figure 16 : Above: cDNA gel electrophoresis of ABCA4 variant c.5018+2T>C transcribed from normal allele and 
mutant sequence *indicates correctly spliced reference sequence Below: schematic representation of gel electrophoresis 
results 
pSPL3b exon 1 pSPL3b exon 2 
194 bp 
pSPL3b exon 1 pSPL3b exon 2 ABCA4 exon 35 
538bp 
*364 bp 
pSPL3b exon 1 ABCA4 exon 35 pSPL3b exon 2 
Intron 35 + pSPL3b 
Product sizes 606 bp and 495 bp analyzed 
by Baier (2014), yet not able to be 
characterized 
c.5018+2T>C 
WT                     Mut 
*364 bp 
538 bp 
538 bp 
495 bp 
606 bp 
194 bp 
194 bp 
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The absence of an RT-PCR product containing correctly spliced exon 35 in the mutant transcript 
is indicative of total loss of splice donor potential at the canonical site due to the variant. The 
in vitro results coincide with in silico predictions that the donor site would be completely 
abolished, even though some donor sites tolerate and use a cytosine at the +2 position.  
 
 In vitro splicing effect of the ABCA4 c.1239+1G>C variant 
As in the previous two examples involving a single nucleotide change at a canonical 
site, all five programmes predicted a complete loss of the regular donor site for this guanine to 
cytosine change in the first base of the splicing donor. 
 
 
Figure 17 : Schematic representation of exon 9, position of ABCA4 variant c.1239+1G>C, and predicted effect of loss 
of donor site 
 
The gel electrophoresis (Fig. 18) revealed a correctly spliced product (334 bp) from amplifying 
cDNA transcribed from the normal allele sequence. The band of 454 bp was generated from 
use of a cryptic acceptor site in ABCA4 intron 9 (c.1239+152/153). The extra exon that was 
included contained sequence from intron 9, as well as pSPL3b vector sequence up to the 
alternative donor site located in the vector. cDNA amplification of the variant sequence cDNA 
failed to produce any correctly spliced product. The strongest visible band (194 bp; 
c.1100_1239del; p.Thr367Serfs*6) contained vector-only sequence. Also detectable was a 
large product (607 bp) generated by correct splicing at the first donor site, but rather than 
splicing at the end of exon 9, the guanine-thymidine donor 2 of the vector was used and included 
pSPL3b intronic sequence. Similarly, some transcripts appear to have arisen from using an 
acceptor at c.1100-45/44 (377 bp).89 The smaller product (308 bp; c.1100_1125del; 
p.Thr367Lysfs*28) is probably the result of using a cryptic acceptor at c.1124/25.89  These latter 
two products could not be sequenced, therefore their nature is merely hypothesized based on in 
silico predictions and congruency with observed sizes. 89 
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Figure 18 : Above: cDNA gel electrophoresis of ABCA4 variant c.1239+1G>C transcribed from normal allele and 
mutant sequence *indicates correctly spliced reference sequence Below: schematic representation of gel electrophoresis 
results 
 
These in vitro results support in silico predictions that the nucleotide change at the +1 position 
causes the regular donor site to become too weak for correct splicing to occur. 
*334 bp 
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4.3 INTRONIC VARIANTS 
 In vitro splicing effect of the ABCA4 c.4773+3A>G variant 
This adenine to guanine change at the +3 position of the intron is a site at which some 
nucleotide variance is tolerated (Fig. 4).  Two of the five programmes predicted a loss of the 
donor site, whereas three merely foresaw a reduction in strength. 
 
 
Figure 19 : Schematic representation of exon 33, position of ABCA4 variant c.4773+3A>G, and predicted effect of 
loss/reduction of donor site 
 
Due to the small intron size between exons 33 and 34, both exons were included in the construct 
to provide a more natural sequence environment. The top band (375 bp) present in both the 
normal allele and mutant cDNA corresponds to the correctly spliced product and includes both 
exon 33 and 34. The bottom band (300 bp; c.4774_4848del; p.Gly1592_Lys1616del) contains 
exon 33 only. As in the previous cases, there is also a band at 194 bp containing vector-only 
sequence (c.4668_4848del; p.Tyr1557Cysfs*45). The smaller 291 bp product probably arose 
from the use of a cryptic donor site from exon 33 and is missing the last nine bases of exon 33 
(c.4765_4773del; p.Val1589_Gly1591del).89 This may have only a minor effect on protein 
function, as only three amino acids are lost.  The product of 269 bp contains only exon 34. 
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Figure 20 : Above: cDNA gel electrophoresis of ABCA4 variant c.4773+3A>G transcribed from normal allele and mutant 
sequence *indicates correctly spliced reference sequence Below: schematic representation of gel electrophoresis results 
 
In the case of c.4773+3A>G, the effect on the protein level as a result of exon skipping is 
difficult to foresee. The nucleotide change is found in exon 33, and whether exon 34 would also 
be skipped in vivo remains speculative.  This appears to be a relatively frequent phenomenon, 
as RNA sequencing by other groups has demonstrated similar results to those for normal allele 
and mutant transcripts observed here. For example, exon 34 may be spliced out in some 
isoforms even in healthy subjects, or both ABCA4 exon 33 and 34 may be skipped.87, 88  Others 
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300 bp 
194 bp 
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  300 bp 
  291 bp 
  269 bp 
194 bp 
pSPL3b exon 1 pSPL3b exon 2 
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pSPL3b exon 1 pSPL3b exon 2 ABCA4 exon 34 
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pSPL3b exon 1 ABCA4 exon 33 pSPL3b exon 2 
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pSPL3b exon 1 ABCA4 exon 33 pSPL3b exon 2 
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report skipping of ABCA4 exon 28 and 29 in normal retinal cells.62  These results, coupled with 
those of this study, seem to indicate that particular regions of ABCA4 can be polyisoformic, 
thus making it difficult to evaluate what impact ABCA4 c.4773+3A>G would truly have in vivo. 
Nevertheless, despite some variance being tolerated at the +3 position, these in vitro results 
support the in silico predictions that this variant would adversely affect mRNA splicing and, at 
the very least, likely reduce the amount of normal protein. 
 In vitro splicing effect of the CNBG3 variant c.991-3T>G  
This thymine to guanidine change at the intronic -3 position was the only CNGB3 
variant included in the study. It was predicted to be spliceogenic and lead to the loss of the 
canonical acceptor site, resulting in an alternative acceptor site and the inclusion of two extra 
bases at the 5′ end of exon 9. 
 
 
Figure 21: Schematic representation of exon 9, position of CNGB3 c.991-3T>G variant, and predicted effect of loss of 
canonical acceptor site and creation of alternative acceptor site 
 
Due to the limited size difference of the transcript generated from the mutant sequence, the 
effect cannot be observed in the gel electrophoresis documentation (Fig.22). However, 
sequencing of the normal allele and mutant RT-PCR products confirmed the in silico prediction 
of a novel acceptor site being used, resulting in a 2 bp insertion (p.Tyr331Serfs*12) and 
complete absence of normal transcript. Because this leads to a frame-shift with a stop codon 
being generated 12 amino acids downstream, the variant has a clear pathogenic effect. The stop 
codon is only 31 bp from the next exon junction, making it unlikely to be degraded by the 
nonsense mediated decay mechanism, 83 thus increasing the pathogenic nature of this variant. 
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Figure 22: Above: cDNA gel electrophoresis of CNGB3 c.991-3T>G variant transcribed from wild-type and mutant 
sequence * indicates correctly spliced reference sequence Below: schematic representation of gel electrophoresis results 
4.4 EXONIC VARIANTS 
Nine of the 21 variants included in this study were exonic. An increasing number of 
studies are focusing on exonic variants’ effect on splicing and their potential disruption of the 
enhancing and silencing motifs necessary for correct exon recognition.50,60,80   
 In vitro splicing effect of the ABCA4 variant c.4919G>A  
This guanine to adenine change mid exon is located 70 bases from the next acceptor 
site. The use of novel cryptic splice sites is a common phenomenon due to exonic variants,51 
and in this case, four of the five in silico tools predicted the abolishment of an existing cryptic 
acceptor site and the creation of another in its vicinity. 
c.991-3T>G 
WT                     Mut 
*259 bp 261 bp 
194 bp 
pSPL3b exon 1 pSPL3b exon 2 
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Figure 23: Schematic representation of exon 35, position of ABCA4 variant c.4919G>A, and predicted effect of loss of 
canonical acceptor site and creation of alternative acceptor site 
 
The gel electrophoresis documentation shows a correctly spliced product obtained from the 
normal allele cDNA (Fig. 24: 364 bp). Additionally, transcripts with vector-only sequence in 
which the region of interest was spliced out are evident (194 bp; c.4849_5018del; 
p.Val1617Alafs*113). The large product of 538 bp arose from the inclusion of intronic 
sequence.89 cDNA amplification of the transcribed variant sequence showed the correctly 
spliced 364 bp product, transcripts void of reference sequence (194 bp), and those with intronic 
inclusion (538 bp). Sequencing confirmed that the 294 bp product arose from a new acceptor 
site being used at c.4919/20 and is missing 72 bp at the 5′ end of exon 35 (c.4850_4921del; 
p.Val1617_Arg1640del). The 464 bp product is hypothesized to have arisen from using an 
acceptor site upstream from the canonical one (c.4849-102/101) and includes intron 34 
sequence.89 
 
 
 
Legend 
Variant 
Donor site 
Acceptor site 
Loss of site 
50 
 
 
 
 
 
 
Figure 24: Above: cDNA gel electrophoresis of ABCA4 variant c.4919G>A transcribed from wild-type and mutant 
sequence *indicates correctly spliced reference sequence Below: schematic representation of gel electrophoresis results 
 
These in vitro results coincide with the in silico predictions that this exonic variant will lead to 
the use of a cryptic splice site and consequently disrupt splicing. 
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 In vitro splicing effect of the ABCA4 variant c.4354G>T 
This guanine to thymine change is near an acceptor site and in silico predictions 
indicated a new donor site being generated at the -1 position directly adjacent to the acceptor 
site. 
 
 
Figure 25: Schematic representation of exon 30, position of ABCA4 variant c.4354G>T, and predicted effect of the 
creation of a novel donor site at the -1 position 
 
As was the case with the CNGB3 c.991-3T>G variant, the high percentage gel electrophoresis 
results (Fig.26) failed to show any visible size differences between the normal allele sequence 
and the variant transcript. Subsequent investigation via sequencing and fragment analysis of the 
cDNA transcribed from the normal allele demonstrated correctly spliced product (381 bp), as 
well as a 308 bp product missing the last 73 bp of exon 30 due to use of a cryptic splice donor 
site (c.4467/68; p.C1490Efs*12). The product of 411 bp is hypothesized to have arisen from 
the use of a donor site downstream from the canonical one (c.4539+31/32), and likely includes 
30 bp of intron 30 (p.Q1513_R1514insVPDLQTTGPQ).89  The large product at 615 bp resulted 
from the inclusion of intronic sequence.89 Fragment analyses revealed that all transcripts 
containing the variant also additionally exist with a four base pair deletion at the 5′  end of the 
exon (304, 377, 407, and 611 bp).89  These findings support in silico predictions that the 
appearance of a new donor site disrupts correct splicing, even though no evidence of the novel 
donor site being used was seen in the in vitro investigation. This may be because the construct 
only contains a small region of the natural intron.  A cryptic acceptor may be present in the 
intervening sequence 29 and including the entire sequence in the construct may have made the 
effect of the mutation giving rise to a novel donor site evident. 
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Figure 26:  Above: cDNA gel electrophoresis of ABCA4 variant c.4354G>T transcribed from normal allele and mutant 
sequence *indicates correctly spliced reference sequence Below: schematic representation of gel electrophoresis results 
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 In vitro splicing effect of the ABCA4 variant c.4457C>T 
This variant is characterized by a cytosine to thymine change four bases from the natural 
acceptor site. A cryptic acceptor site exists mid-exon and all programmes predicted it to gain 
in strength as a result of the variant. 
 
 
 
Figure 27: Schematic representation of exon 30, position of ABCA4 variant c.4457C>T, and predicted effect of increased 
exonic cryptic acceptor site strength due to the variant, as indicated by the yellow highlighting 
 
Analogous to variant ABCA4 c.4354G>T, no visible size difference between the normal and 
mutant cDNA could be detected in the high percentage gel electrophoresis and sequencing also 
failed to reveal evidence of alternative splicing behaviour in the mutant product. The reference 
sequence of 381 bp is evident in both,  the large product of 615 bp due to intronic inclusion, 89 
the product of 308 bp with the 73 bp deletion resulting from the use of a cryptic donor site, and 
the transcript of 194 bp containing vector-only sequence. The product of 411 bp is thought to 
have arisen from using a donor site downstream from the canonical one, and likely contains 30 
bp of intron 30.89  
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Figure 28: Above: cDNA gel electrophoresis of ABCA4 variant c.4457C>T transcribed from normal allele and mutant 
sequence * indicates correctly spliced reference sequence Below: schematic representation of gel electrophoresis results 
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 In vitro splicing effect of the ABCA4 variant c.6732G>A 
This guanidine to adenine change is two bases away from the canonical acceptor site 
and four of the five programmes predicted the appearance of a novel donor site at the -1 position 
adjacent to the acceptor site. For this reason, this variant was a particularly interesting case to 
include in the study. 
 
 
Figure 29: Schematic representation of exon 49, position of ABCA4 variant c.6732G>A, and predicted effect of the 
appearance of a novel donor site 
 
Gel electrophoresis and sequencing of the cDNA products revealed that both the normal allele 
and mutant had been correctly spliced, as well as produced transcripts in which intronic 
sequence from the pSPL3b vector had been included.  
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Figure 30: Above: cDNA gel electrophoresis of ABCA4 variant c.6732G>A transcribed from normal allele and mutant 
sequence * indicates correctly spliced reference sequence Below: schematic representation of gel electrophoresis results 
 
4.5 SUMMARY OF RESULTS 
Functional analyses of all canonical (N=3) and intronic variants (N=2) completed in this 
study demonstrated aberrant splicing in accordance with in silico calculations. Of the four 
exonic variants completed, in silico predictions of abnormal splicing could be verified in vitro 
for two (Table 32). For the remaining two, including additional sequence to better replicate 
natural splicing conditions may have increased the sensitivity of the exon-trapping system and 
thus produced more significant in vitro results. 
 
Type of  
Variant 
Variant Product Size 
(bp) 
Effect on splicing Putative Effect 
on Protein 
Canonical ABCA4 
c.5312+1G>A 
310  Reference sequence 
  194 c.5197_5312del 
(exon spliced out) 
p.Asn1734Glyfs*14 
Canonical ABCA4 
c.5018+2T>C 
538 Intron retention - 
prediction not possible 
 
  364 Reference sequence  
  194 Exon spliced out p.Val1617Alafs*113 
Canonical ABCA4 
c.1239+1G>C 
607 Intron retention - 
prediction not possible 
 
  454 c.1239+152/153 acceptor  
  377* c.1100-45/44 acceptor  
  334 Reference sequence  
  308* c.1124/25 acceptor; 
c.1100_1125del 
p.Thr367Lysfs*28 
  194 c.1100_1239del  
(exon spliced out) 
p.Thr367Serfs*6 
Intronic ABCA4 
c.4773+3A>G 
375 Reference sequence  
  300 c.4774_4848del  
(exon 34 deleted) 
p.Gly1592_Lys1616del 
  291 c.4765/66 donor; 
c.4765_4773del 
p.Val1589_Gly1591del 
  269 c.4668_4773del  
(exon 33 deleted) 
p.Tyr1557Alafs*18 
  194 c.4668_4848del  
(exon spliced out) 
p.Tyr1557Cysfs*45 
 
 
 
 
 
 
  
 
pSPL3b exon 1 pSPL3b exon 2 
*281 bp 
ABCA4 exon 49 
474 bp 
pSPL3b exon 1 pSPL3b exon 2 ABCA4 exon 49 
Intron 49 
Product size 474 bp analyzed by Baier (2014) 
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Intronic CNGB3 
 c.991-3T>G 
261 p.Tyr331Serfs*12 
  259 Reference sequence  
Exonic ABCA4 
c.4919G>A 
538* Intron retention - 
prediction not possible 
 
  464* c.4849-102/101 acceptor  
  364 Reference sequence  
  294 c.4919/20 acceptor; 
c.4850_4921del 
p.Val1617_Arg1640del 
  194 c.4849_5018del  
(exon spliced out) 
p.Val1617Alafs*113 
Exonic ABCA4  
c.4354G>T 
615* Intron retention - 
prediction not possible 
 
  611* c.4355/56 acceptor  
Intron retention –
prediction not possible 
 
  411* c.4539+31/32 Donor p.Q1513_R1514insVPDL
QTTGPQ 
  407* c.4355/56 acceptor + 
c.4539+31/32 donor 
p.E1452Tfs*86 
  381 Reference sequence  
  377* c.4355/56 acceptor p.E1452Tfs*73 
  308 c.4467/68 donor p.C1490Efs*12 
  304* c.4355/56 acceptor + 
c.4467/68 donor 
p.E1452Tfs*77 
  194 c.4353_4539del  
(exon spliced out) 
p.W1453Hfs*11 
Exonic ABCA4  
c.4457C>T 
615* Intron retention - 
prediction not possible 
 
  411* c.4539+31/32 donor p.Q1513_R1514insVPDL
QTTGPQ 
  381 Reference sequence  
  308 c.4467/68 donor p.C1490Efs*12 
  194 c.4353_4539del (exon 
spliced out) 
p.W1453Hfs*11 
Exonic ABCA4 
c.6732G>A 
474 Intron retention - 
prediction not possible 
 
  281 Reference sequence  
Table 32: Summary of in vitro analyses 
Variants grouped according to type and in descending cDNA position, with the exception of ABCA4  
c.4457C>T and ABCA4 c.6732G>A. Those marked * were analyzed via fragment analysis by Baier (2014). 
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5 DISCUSSION 
Experiments for this medical dissertation focused on functional in vitro analyses of 
twenty ABCA4 variants and one CNGB3 found in retinal degeneration patients, all of which had 
been predicted in silico to affect splicing.  Because ABCA4 and CNGB3 are transcribed 
exclusively in the retina, using native tissue for direct in vitro splicing analyses was not 
possible. Instead, an established method of exon-trapping using the pSPL3b vector was 
employed. Of the nine variant analyses fully completed during the time of this dissertation, 
seven demonstrated disrupted splicing behaviour in vitro. 
All three canonical site variants (ABCA4 c.5018+2T>C, ABCA4 c.5312+1G>A, ABCA4 
c.1239+1G>C) produced in vitro results matching those foreseen by in silico tools. Subsequent 
analyses of the putative effect on protein translation suggested that all three would likely lead 
to a frameshift with varying consequences, including intron retention and exon skipping. Both 
intronic variants also demonstrated aberrant splicing behaviour with the putative effect ranging 
from reduced protein synthesis (ABCA4 c.4773+3A>G), to a frameshift with a premature stop 
codon (CNGB3 c.991-3T>G). Conversely, two of the four exonic variants predicted in silico to 
be spliceogenic failed to produce in vitro results that confirmed this (ABCA4 c.4457C>T, 
ABCA4 c.6732G>A).  
These findings highlight the great complexity involved in predicting and correctly 
interpreting the effect a variant may have. Also, they underscore the importance of utilizing in 
vitro analysis as a follow-up to in silico predictions for genes linked to retinal degenerative 
disease, as is done for genes implicated in breast and ovarian cancer and autosomal dominant 
polycystic kidney disease. 73, 101 In vitro analyses of retinal tissue undoubtedly play a 
fundamental role in enhancing current knowledge on potential variant effects, yet also pose 
several challenges and limitations. In addition to obstacles in obtaining viable retinal tissue, the 
retina displays even more diverse alternative splicing and novel gene transcription activity than 
previously assumed, 88 and there also appears to be retina-specific splice factors.106 Vector 
systems for in vitro investigation constitute fabricated, static environments and cannot possibly 
replicate the great intricacy and manifoldness of tissue specific splicing factors at work in the 
neural retina. Consequently, caution must be exercised when interpreting in silico results to 
avoid faulty assumptions regarding the in vivo situation. 
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5.1 IN SILICO - IN VITRO ANALYSES  
The agreement between the in silico-in vitro results for single nucleotide substitutions 
at canonical sites is due to the high degree of conservation found at these sites. An abundance 
of data is available on the various nucleotide frequencies at intron-exon boundaries and can be 
drawn upon when developing algorithmic scoring systems for bioinformatics programmes. 
Consequently, in silico prediction accuracy for canonical sites is quite reliable and this study’s 
findings are consistent with those of other groups.53, 63, 64   
Even though it was not surprising that all three canonical variants led to splicing 
alterations as predicted in silico, it is important to note that single base exchanges at canonical 
sites cannot automatically be assumed to cause splicing aberrations. At least one variant at a 
canonical site (BRCA2 c.8331+1G>T) is described in the literature as having been predicted by 
bioinformatics to cause splicing aberration, yet in vitro results failed to confirm this.40 
There are several issues to consider regarding the discrepancy between in silico 
predictions and the in vitro findings of this and other studies. Incongruity may be partially due 
to current software’s limitations in assessing variants outside the canonical sites. Although the 
nature of exonic splicing regulatory elements and their role in Mendelian disease remain poorly 
understood,  there is evidence suggesting that up to 25% of exonic mutations affect splicing. 65, 
66   Despite this high frequency, in silico tools still appear lacking in their ability to accurately 
analyse exonic variants. For example, Théry et al. 52 reported a 55 % false negative in silico 
prediction rate for internal exonic variants (BRCA1/BRCA2) which had subsequently been 
subjected to in vitro follow-up analyses - a shortcoming that could have serious clinical 
implications. Conversely, Claverie-Martin et al. investigated 32 exonic mutations predicted by 
bioinformatics to be spliceogenic, of which only three demonstrated splicing defects in vitro.101 
Computational tools can only increase in accuracy as more data is generated to fine-tune 
existing algorithms and improving in silico assessment of exonic variants’ effects on splicing 
has become the focus of recent efforts. 102     
Despite persisting imperfections, bioinformatics play an integral role in the molecular 
diagnosis process. In addition to enabling the spliceogenic potential of variants to be studied in 
genes with expression restricted to specialized/non-accessible tissue, as is the case for ABCA4 
and CNGB3, computational prediction is key to establishing a priority hierarchy for further 
analyses. Variants deemed in silico most likely to be spliceogenic can be subjected a priori to 
functional splicing analysis. This has obvious clinical and economic advantages. Nonetheless, 
a priori testing does not circumvent the problem of high false negative rates. Relying solely on 
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in silico results poses the danger of leaving false negative patients “under-investigated” and 
therefore under-diagnosed.  Despite on-going development on the frontiers of bioinformatic 
prediction tools,103 to date we are still reliant on functional analyses for verification. 104 This 
process, albeit resource-consuming, minimizes the risk of missing mutations deemed non-
spliceogenic in silico and is necessary for characterising and cataloguing the nature of aberrant 
transcripts.  
Functional analyses serve as an instrumental source of empirical bio data for software 
tools and aid in the diagnostic process, yet as already discussed, pose several drawbacks. Exon 
trapping is an artificial system that includes only short segments of natural introns and presents 
the danger of disrupting or eliminating important splicing regulatory elements.57 For this reason, 
it can be beneficial to include additional neighbouring sequence as a means of replicating a 
more natural splicing environment. Doing so for variants such as ABCA4 c.6732G>A, 
c.4457C>T, and even c.4354G>T, may have led to more conclusive in vitro results, yet a larger 
construct size generally requires the tedious undertaking of  increased cloning work. In the case 
of variant ABCA4 c. 6732G>A, the prediction was for a donor site to appear at the beginning 
of exon 49. Ideally, approximately 50 bp of intron 47, and then exon 48, intron 48 and exon 49 
containing the variant should have been included, leading to a construct with 1850-1900 extra 
base pairs. In this case, the chosen pSPL3b expression vector would not have been suitable, as 
other groups have found it unable to retain inserts > 1kb.100 The in vitro method of exon-
trapping is likely not sensitive enough to detect subtle splicing defects, and utilizing a vector 
system with endogenous splice sites for certain variants may have proven to be more effective.99  
In fact, five years after the experiments for this dissertation were completed, Sangermano et al. 
addressed precisely this issue by designing a robust multi-exon midigene construct which 
allowed for the reliable assessment of functional consequences of putative splice defects.105 
Despite their numerous shortcomings, in silico and in vitro analyses are complementary 
procedures allowing researchers and clinicians to first prioritize variants of unknown 
significance before commencing with expensive, time-consuming functional assessments. 
5.2 ABCA4 TOPOLOGY AND DOMAINS AFFECTED BY ABERRANT SPLICING 
Following in vitro analyses, the putative effect that the aberrant transcripts may have on 
the protein level was examined.89 Fig. 31 provides a schematic representation of human ABCA4 
topology, 22 including the location of the protein changes that may arise as a result of the variants 
analyzed in this study.  
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Six of the seven variants which displayed aberrant splicing in vitro lie within domains 
found in the extracellular loops (Fig. 1 & Fig 31: ECD1, ECD2) on the rims of the rod outer 
segment discs (Fig. 2 & Fig.31). The biological significance of these domains has yet to be 
fully clarified,19 yet research suggests that the binding of all-trans-retinal causes the otherwise 
highly stable secondary structure of ECD2 to undergo important conformational changes 
necessary for proper substrate transport.85  Similarly, it has also been demonstrated for ABCA1, 
another A class ABC transporter, that the two large extracellular domains play an instrumental 
role in transport processes by mobilizing cellular phospholipids to apolipoprotein A-I.86  These 
findings imply that structural alterations in the ECD2 caused by disease-associated mutations 
may impede the clearance process,85 resulting in all-trans-retinal accumulation in the interdiscal 
space and ultimately the formation of retina-toxic lipofuscin. 
The pathogenic significance of the frameshift mutations located within the ECD 
domains is obvious, as they will likely lead to a truncated protein. The effect of the other two 
(ECD2: c.4773+3A>G; c.4919G>A) however, is less apparent because they show deletions of 
various sizes. In such cases, it is conceivable that the ensuing protein could, in fact, retain 
enough of its function to only minimally alter the phenotype, perhaps even leaving it unaffected.  
Such scenarios may partially account for the considerable phenotypic variance found in 
Stargardt disease. 99 
The putative effect of variant ABCA4 c.5312+1G>A is a truncated protein, potentially 
resulting in the loss of the intracellular C-terminal in one of the transmembrane domains (Fig. 
31: p.Asn1734Glyfs*14). Each transmembrane domain consists of six membrane-spanning 
helices and the flipping of NRPE from the luminal to the cytoplasmic side of the disc membrane 
is brought about by conformational changes caused by ATP binding to the intracellular 
nucleotide binding domains (Fig.2).19  Although a truncating mutation in the C-terminal could 
theoretically still result in a protein being incorporated into the membrane and allow for a 
certain degree of functionality,99  it is likely to disrupt the clearance process and lead to an 
accumulation of retinal toxic by-products. 
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Figure 31: *Human ABCA4 topology showing the variants investigated in this study and their corresponding 
putative protein effect (red). 
*own schematic figure based on Tsybovsky et al., 201022 (Fig.2 p.16) Numbers:  position of corresponding residues in 
primary structure; ECD1, ECD2: exocytoplasmic domains 1 & 2; NBD1, NBD2: nucleotide binding domains 1&2  
 
5.3 CONSIDERATIONS FOR SPLICING AND DISEASE 
 Splice site variants constitute approximately 15% of registered pathogenic 
mutations 49,74 and some evidence suggests that 22% of mutations previously classified as 
missense may in fact also affect splicing. 66 Based on these findings, up to one third of all 
pathogenic mutations may be implicated in mRNA splicing disruption, yet despite this high 
occurrence rate it remains difficult to pinpoint a splicing defect as the cause of a disease. The 
act of mRNA splicing is highly complex, involving intricate cooperation among numerous 
elements. Depending on the location of the variant, a wide variety of outcomes can result, 
ranging from exon-skipping, activation of a cryptic splice site, or the inclusion of intronic 
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p.Asn1734Glyfs*14 
63 
 
sequence. Ensuing consequences on the protein level are often frameshifts, or in-frame 
deletions/insertions, and therefore may be difficult to decipher from truncating mutations or 
deletions/insertions resulting from other genetic mechanisms.71 On the other hand, incomplete 
protein expression, as well as tissue specificity, tend to be characteristic of splicing mutations.75 
In considering the effects of aberrant splicing, there may be less obvious factors to 
consider apart from direct protein consequences.  For instance, variants may have an effect on 
the physiological process of alternative splicing, which involves the generation of various 
transcripts necessary for functional diversity, and also plays an important role in regulating 
gene expression.44 Intronic variants creating cryptic splice sites, or de novo silencer or 
enhancers, have been linked to the deregulation of alternative splicing, 77 thus affecting the 
isoforms of the mRNA and ultimately influencing phenotype manifestation. Beit-Ya’acov et al.  
investigated the effects of a novel ABCA4 splicing variant on protein expression and were 
surprised to obtain, in addition to the normal allele transcript, three alternatively spliced 
transcripts in healthy retina RNA; the diseased transcript contained only the alternatively 
spliced isoforms.62 These findings highlight the great difficulty researchers and clinicians face 
when trying to deduce a genotype-phenotype correlation in mutations affecting splicing, which 
may hold significance for therapy. 
At present, various treatment options are being investigated in clinical trials for STGD1, 
including gene replacement therapy (NCT01367444; NCT01736592), subretinal 
transplantation of human embryonic stem cell-derived retinal pigmented epithelial cells 
(NCT02445612; NCT02941991) as well as the administration of C20-D3 retinylacetate 
(NCT02402660).107 Specific to splicing but still in the experimental phase, one group 
demonstrated that ABCA4 pre-mRNA splicing defects in photoreceptor precursor cells 
generated from STGD1 patient fibroblasts can be rescued by administrating antisense 
oligonucleotides to redirect the defect to either  include or skip the (pseudo)exons.107  
5.4 CURRENT EFFORTS FOCUSING ON ABCA4 VARIANTS AND SPLICEOGENIC 
EFFECTS 
Of the 791 HGMD publicly-registered ABCA4 mutations, 117 (15%) are classified as 
spliceogenic (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ABCA4; Appendix: Table 33). 68 
(~58%) are canonical, 43 (~37%) are found at the splice site border, and 6 (0,5%) are deep 
intronic variants. This study investigated twenty-one variants predicted in silico to affect 
splicing, which could potentially add ~ 18% to the existing data.  Of the nine completed variants 
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for this dissertation, six were located outside the highly conserved splice sites - two at the 
intronic splice site border and four exonic variants. Four of the six (~67%) produced 
spliceogenic in vitro results. The subsequent completion of the remaining variants by Baier 
(2014) showed similar findings: five of the thirteen (~38%) exonic variants produced aberrant 
splice products, and two additional exonic variants led to differentially spliced isoforms.89  
In order to assess similar efforts focusing on functional analyses of ABCA4 spliceogenic 
mutations, in particular those outside the highly conserved positions, a literature search of the 
PubMed database was conducted by combining “ABCA4” with the following keywords:  
“splicing”, “exonic”; “intronic” “in vitro”; “functional assay” and “exon trapping.”  This 
yielded a meager total of seventeen studies focusing on ABCA4 functional assays between 1997 
when ABCA4 was discovered 78 and 2018 (Appendix: Table 35).  
Although this search cannot claim to be fully exhaustive, the scarcity of publications in 
the past two decades suggests that this is an area in need of increased attention. Exonic variants 
are more abundant and potentially pathogenic than previously assumed. 51,72,79 By activating de 
novo ectopic splice sites, exonic variants can show deleterious effects,51 as was found by 
Moseley et al.80 in their research on autosomal recessive growth hormone deficiency; or Sheikh 
et al.81 in the MECP2 gene causing Rett syndrome. Furthermore, single nucleotide changes 
within the coding region have also been implicated in disease by means of disrupting splicing 
silencer and enhancer motifs, consequently leading to aberrant splicing.79, 82  
The growing body of research investigating putative effects of noncanonical splice site 
variants, the heightened demand for personalised medicine, and importance of clearly 
discerning the nature of variants of unknown significance, all underscore the necessity of 
performing functional in vitro splicing analyses. Only as more in vitro or in vivo data is gathered 
will it be possible to optimize the in silico prediction algorithms and generate more reliable 
predictions. As indicated by the marginal results found in the literature search conducted by 
this study, there is certainly room for improvement if medicine and science are to better serve 
patients suffering from retinal dystrophies. A thematic approach study in the UK involving 200 
patients with inherited retinal disease explored patient understanding of/attitudes towards 
genetic testing. It was revealed that > 90% were in support of publicly funded diagnostic and 
predictive genetic testing, and also felt that genetic counselling should precede testing, yet 
paradoxically ~60% admitted to having a very limited understanding of what genetic testing 
even entailed.90   In light of this, the suggestion brought forth by Spurdle et al. (2008) seems to 
be worth considering, namely that functional testing to generate in vitro/ in vivo data ideally 
take place in clinical settings. Bridging the gap between research centers and primary patient 
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care facilities could help heighten patient awareness and maximize counselling benefits.40 
Moreover, funding could be made dependent on agreeing to share empirical results in databases 
and publications.40  This would increase the availability of data and propagate the 
characterization of variants, which is crucial to evaluating their clinical significance. Such a 
system could greatly benefit the wider retinal degeneration patient community, as well as aid 
clinicians and researchers in their work. 
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6 SUMMARY 
This study conducted in vitro analyses to investigate the splicing effects of twenty 
ABCA4 variants and one CNGB3, which had been predicted in silico to cause aberrant mRNA 
splicing. To circumvent the problem of tissue availability, the method of in vitro exon trapping 
was employed, based on the work of Cepko et al., 55 which capitalizes on the highly conserved 
sequences flanking splice sites, and implements transmissible expression vectors to generate 
and recover genomic inserts.56, 57 Following replication and selection in E.coli, the pSPL3b 
vector containing the construct was transfected in transient cells, the RNA isolated, reverse 
transcribed, and RT-PCR amplified. Visualizing the products via gel electrophoresis allowed 
for an initial comparison of splicing activity between the normal allele and mutant variants.  Of 
the twenty-one variant analyses, nine were completed within the allotted timeframe for this 
medical dissertation. Seven variants (three canonical, two intronic, and two exonic) 
demonstrated disrupted splicing behaviour in vitro in accordance with in silico predictions. 
 
Diese Studie führte in vitro Analysen durch, um das Spleißverhalten von zwanzig ABCA4-
Varianten und einer CNGB3-Variante zu untersuchen, bei denen in silico Vorhersagen darauf 
hindeuteten fehlerhaftes MRNA-Spleißen zu erwarten. Um das Problem der 
Gewebeverfügbarkeit zu umgehen, wurde die sogenannte in-vitro-Exon-Trapping-Methode 
angewandt, welche sich auf die Arbeit von Cepko et al. 55 bezieht und die hochkonservierten 
Sequenzen, die die Spleißstellen flankieren, zu Nutze macht. Übertragende 
Expressionsvektoren wurden eingesetzt, um genomische Inserts zu erzeugen bzw. 
wiederzugewinnen. Nach der Replikation und Selektion in E. coli wurde der pSPL3b-Vektor 
mit dem eingeschlossenen Konstrukt in transienten Zellen transfiziert, die RNA isoliert, revers 
transkribiert und RT-PCR amplifiziert. Die Visualisierung der Produkte mittels 
Gelelektrophorese ermöglichte einen ersten Vergleich des Spleißverhaltens zwischen den 
gesunden und mutierten Varianten. Von den insgesamt 21 untersuchten Varianten wurden neun 
innerhalb des zugewiesenen Zeitrahmens dieser Dissertation abgeschlossen. Sieben davon (drei 
kanonische, zwei intronische, sowie zwei exonische) zeigten in Übereinstimmung mit den in 
silico-Vorhersagen ein gestörtes Spleißverhalten in vitro. 
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 Canonical Variants Splice Site Intronic 
Variants 
Deep Intronic  
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Total 
68 43          6 117 
Table 34: Summary of HGMD-registered ABCA4 splice mutations 
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(ABCA4) mutations in a family with Stargardt disease and retinitis pigmentosa. Invest 
Ophthalmol Vis Sci. 42(12):2757-61. 
in vitro testing of expression 
Schroyer NF, Lewis RA, Yatsenko AN, Wensel TG, Lupski JR (2001b).Cosegregation 
and functional analysis of mutant ABCR (ABCA4) alleles in families that manifest 
both Stargardt disease and age-related macular degeneration. Hum Mol Genet.217 
(2):11-4. 
in vitro testing of expression and ATP 
binding 
Biswas-Fiss E.E (2003). Functional analysis of genetic mutations in nucleotide 
binding domain 2 of the human retina specific ABC transporter. Biochemistry. 
42:10683–10696. 
in vitro site-directed mutagenesis to 
investigate effect of mutated NBD2 
proteins 
Yatsenko AN, Shroyer NF, Lewis RA, Lupski JR (2003). An ABCA4 genomic 
deletion in patients with Stargardt disease. Hum Mutat. 23(5):523. 
in vitro studies of deletion mutation 
on protein expression 
Wiszniewski W, Zaremba CM, Yatsenko AN, Jamrich M, Wensel TG, Lewis RA, 
Lupski JR (2005). ABCA4 mutations causing mislocalization are found frequently in 
patients with severe retinal dystrophies. Hum. Mol. Genet. 14:2769–2778 
in vitro testing of ABCA4 missense 
mutations on protein processing 
Beit-Ya’acov A, Mizrahi-Meissonnier L, Obolensky A, Landau C, Blumenfeld A, 
Rosenmann A, Banin E, and Sharon D (2007). Homozygosity for a novel ABCA4 
founder splicing mutation is associated with progressive and severe Stargardt-like 
disease. Invest. Ophthalmol. Vis. Sci. 48, 4308–4314. 
in vitro testing of protein expression 
by RT-PCR 
Albert SSR, Bax N, Roosing S, van den Born L, den Engelsman-van Dijk A, Ramlal 
A, Stone E, Hoyng C, Cremers F (2015). Towards the identification of deep-intronic 
ABCA4 mutations in Stargardt patients by using induced pluripotent stem cell-derived 
photoreceptor progenitor cells. Association for Research in Vision and Ophthalmology 
56(7):3174. 
sequence analysis of ABCA4 mRNA 
from iPSCs differentiated into PPCs 
Bax NM., Sangermano R, Roosing S, Thiadens A A, Hoefsloot LH, den Born L., Phan 
M, Klevering BJ, Westeneng‐van Haaften C, Braun TA, Zonneveld‐Vrieling MN, 
Wijs I, Mutlu M, Stone EM, den Hollander  AI, Klaver CC, Hoyng, CB, Cremers FP 
(2015). Heterozygous deep‐intronic variants and deletions in ABCA4 in persons with 
retinal dystrophies and one exonic ABCA4 variant. Human Mutation, 36: 43-47. 
Exonic variant 
Gérard X, Perrault I, Munnich A, Kaplan J, Rozet JM (2015). Intravitreal injection of 
splice-switching oligonucleotides to manipulate splicing in retinal cells. Mol Ther 
Nucleic Acids. 2015 Sep 1;4. 
Therapy option 
Sangermano R, Bax NM, Bauwens M, van den Born LI, De Baere E, Garanto A, 
Collin RW, Goercharn-Ramlal AS, den Engelsman-van Dijk AH, Rohrschneider K, 
Hoyng CB, Cremers FP, Albert S (2016). Photoreceptor progenitor mRNA analysis 
reveals exon skipping resulting from the ABCA4 c.5461-10T→C mutation in 
Stargardt Disease. Ophthalmology;123(6):1375-85.  
PPC mRNA analysis, in vitro mingene 
analysis  
Aukrust I, Jansson RW, Bredrup C, Rusaas HE, Berland S, Jørgensen A, Haug MG, 
Rødahl E, Houge G, Knappskog PM (2017). The intronic ABCA4 c.5461-10T>C 
variant, frequently seen in patients with Stargardt disease, causes splice defects and 
reduced ABCA4 protein level. Acta Ophthalmol. 95(3):240-246. 
mRNA analysis, protein analysis 
Schulz HL, Grassmann F, Kellner U, Spital G, Rüther K, Jägle H, Hufendiek K, 
Rating P, Huchzermeyer C, Baier MJ, Weber BH, Stöhr H (2017). Mutation spectrum 
of the ABCA4 Gene in 335 Stargardt disease patients from a multicenter German 
cohort-impact of selected deep intronic variants and common SNPs. Invest 
Ophthalmol Vis Sci. 1;58(1):394-403. 
in vitro splicing assay 
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Sangermano R, Khan M, Cornelis SS, Richelle V, Albert S, Garanto A, Elmelik D, 
Qamar R, Lugtenberg D, van den Born LI, Collin RWJ, Cremers FPM (2017).  
ABCA4 midigenes reveal the full splice spectrum of all reported noncanonical splice 
site variants in Stargardt disease. Genome Res. 2018 Jan;28(1):100-110. 
Midigene analysis of splicing effect 
Jonsson F, Westin IM, Österman L, Sandgren O, Burstedt M, Holmberg M, Golovleva 
I. (2018). ATP-binding cassette subfamily A, member 4 intronic variants 
c.4773+3A>G and c.5461-10T>C cause Stargardt disease due to defective splicing. 
Acta Ophthalmol. Epub ahead of print 
Minigene analysis of splicing effect 
Albert S, Garanto A, Sangermano R, Khan M, Bax NM, Hoyng CB, Zernant J, Lee W, 
Allikmets R, Collin RWJ, Cremers FPM (2018). Identification and rescue of splice 
defects caused by two neighboring deep-intronic ABCA4 mutations underlying 
Stargardt disease. Am J Hum Genet. Apr 5;102(4):517-527.  
Therapy option 
Garces, F, Jiang K, Molday, LL, Stöhr, H, Weber BH, Lyons CJ, Maberley D., 
Molday, RS (2018). Correlating the expression and functional activity of ABCA4 
disease variants with the phenotype of patients with Stargardt disease. Invest 
Ophthalmol Vis Sci.2018;59:2305-2315. 
 
Table 35: 17 Publications gleaned from PubMed* search listed by date in ascending order. 
*http://www.ncbi.nlm.nih.gov/ 
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Exon       Variant Cloned construct 
 
9 ABCA4 c.1239+1G>C GAATTCaatcct ccagcatggagt tg aatgagacatgtgatgtggatacact aatgac ta ta t t
gaggt t acaagcaatggggagt t t c tgt aaaatc tg tccct tgt c tcctg gcagCATCCTTTT
GTAATGCATTGATCCAGAGCCTGGAGTCAAATCCTTTAACCAAA
ATCGCTTGGAGGGCGGCAAAGCCTTTGCTGATGGGAAAAATCG
TACACTCCTGATTCACCTGCAGCACGAAGGATACTGAAGAAT gta
agatcccagctgggct tgcct tgtgt accctggacct cccagaagtgtgtg tgtg tgtgtgtgtgtg
tgagagagatgtgcct tcctggtagcacatct catgt t t gt t t t t t gctaagtggactct tgcg t t t cc
tcccccat ccacagtca tcac tggaatgct t t gct tcagtg GGATCC  
 
30 
 
ABCA4 c.4354G>T 
 
GAATTCagaggaggaggaaagggt tg ggcacaat t t c t t a tgcct agggat t t gtcagcaac
t t tgaggctgat t a tggaatat t t t c t t gt c t t ccatgag GGAGTACCCCTGTGGCAAC
TCAACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCA
GCTGTTCCAGAAGCAGAAATGGACACAGGTCAACCCTTCAC CA
TCCTGCAGGTGCAGCAC CAGGGAGAAGCTCACCATGCTGCCAG
AGTGCCCCGAGGGTGCCGGGGGCCTCCCGCC CCCCCAGgtacctga
cct ccaaacaacggggccccaggtctgcctgccacagagggactaggggagtccc tggtat c t c
ctgagtct c tcacaaact aacat t t caaactggcagt tga gtaggggac taaaccaaact ccctgc
accGGATCC 
 
30 ABCA4 c.4457C>T GAATTCagaggaggaggaaagggt tg ggcacaat t t c t t a tgcct agggat t t gtcagcaac
t t tgaggctgat t a tggaatat t t t c t t gt c t t ccatgag GGAGTACCCCTGTGGCAAC
TCAACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCA
GCTGTTCCAGAAGCAGAAATGGACACAGGTCAACCCTTCAC CA
TCCTGCAGGTGCAGCAC CAGGGAGAAGCTCACCATGCTGCCAG
AGTGCCCCGAGGGTGCCGGGGGCCTCCCGCCCCCCCAG gtacctga
cct ccaaacaacggggccccaggtctgcctgccacagagggactaggggagtccc tggtat c t c
ctgagtct c tcacaaact aacat t t caaactggcagt tga gtaggggac taaaccaaact ccctgc
accGGATCC  
 
33_34 
 
ABCA4 c.4773+3A>G 
 
GAATTCt t tgtaaag tggagcca tgt tg ct cgctggtccaggcaat tcccccgaaagt tcatgt
t tccct acaaaacccgagagagctactagtaggcgtgaagt tcgtggccc tggtctgaggat t t cc
tgt t tcct tgt cagGTATGGAGGAATTTCCATTGGAGGAAAGCTCCCAG
TCGTCCCCATCACGGGGGAAGCACTTGTTGGGTTTTTAAGCGAC
CTTGGCCGGATCATGAATGTGAGCGGG gtatgt aaacagactggagat t t ga
gtaggat t t t t gact tgct t aact accatgaatgagaaact ctcatgagtgat aacaggaaaaaaaa
at t aaaaccgtc t tgt t t gt t t gt t tacatgg t t t t t ag GGCCCTATCACTAGAGAGGC
CTCTAAAGAAATACCTGATTTCCTTAAACATCTAGAAACTGAAG
ACAACATTAAGgtact tgaccta tg ta t aat c tgct c tgga t t t gt aaagtggagccatgt
GGATCC 
 
35 ABCA4 c.4919G>A GAATTCatccct cct cctgctgaaat ct agcaaggaa tg tc t tccagctaccaaaccct t cctg
ct t c tcaaat t tcct t tcct t cactgat t tc tgct t t aact agctgt tagtgcagcgtct cagatgt cct
c tccaccctc tagGTGTGGTTTAATAACAAAGGCTGGCATGCCCTGGT
CAGCTTTCTCAATGTGGCCCACAACGCCATCTTAC GGGCCAGCC
TGCCTAAGGACAGGAGCCCCGAGGAGTATGGAATCACCGTCAT
TAGCCAACCCCTGAACCTGACCAAGGAGCAGCTCTCAGAGATT
ACAGTgtaagccaccacagccccagcc tcaccact t tc t t gtcacct tc tccactc t t t gaaca t
cctgagaggat t c tcaccacc GGATCC 
 
35 ABCA4 c.5018+2T>C GAATTCatccct cct cctgctgaaat ct agcaaggaa tg tc t tccagctaccaaaccct t cctg
ct t c tcaaat t tcct t tcct t cactgat t tc tgct t t aact agctg t tagtgcagcgtct cagatgt cct
c tccaccctc tagGTGTGGTTTAATAACAAAGGCTGGCATGCCCTGGT
CAGCTTTCTCAATGTGGCCCACAACGCCATCTTAC GGGCCAGCC
TGCCTAAGGACAGGAGCCCCGAGGAGTATGGAATCACCGTCAT
TAGCCAACCCCTGAACCTGACCAAGGAGCAGCTCTCAGAGATT
ACAGTgtaagccaccacagccccagcc tcaccact t tc t t gtcacct tc tccac tc t t t gaaca t
cctgagaggat t c tcaccacc GGATCC  
 
37 
 
ABCA4 c.5312+1G>A 
 
GAATTCgggtggggtaggag gactagtgacagct taacat a tgt t t gccaaccaagaactgt
t taaaaagcaagtcgaat cagaa tcccagaccct acgagctggaggagcctggccccacccct c
at t t t gcagagc tggcagcaggtctgagaggt t aagtgact tgct c t cct c t tc t c t t t ccgag AT
79 
 
GAATTATTCCGTGAGTGCTGGGCTGGTGGTGGGC ATCTTCATCG
GGTTTCAGAAGAAAGC CTACACTTCTCCAGAAAACCTTCCTGCC
CTTGTGGCACTGCTCCTGCTGTATGG gtaagccgt t t gggccat t agct aa tgc
ctc tgaagagaagcctggtggtgggggtggg gga tcat c t cc tgacagaaaacctgggc tg t G
GATCC 
49 ABCA4 c.6732G>A GAATTCtaccagcagggctgt a tgtg aactgtggaaaat agagagcaaagtgggtaggtgg
gtgt agggtgctgt t t t cctggaaa t atc tacc taat c tcgct ct t c t c t tacct c tagGTGTTTG
TAAATTTTGCTAAACAGCAGACTGAAAGTCATGACCTCCCTCTG
CACCCTCGAGCTGCTGGAGCCAGTCGACAAGCCCAG gtacccc tgct
gc t ta tgcagtccacagct tgaggcagt tcct tggctcagagcccagc tggt t cactgggc t tgag
t tgct ccaaggctcagata tgcc GGATCC 
 
9 
 
CNGB3 c.991-3T>G 
 
ccatgctataaaatgtactgtccagaggaaaatatcactaaacaggatcttggtttttttaaaaagacatatgaatgaaattattttc
agtaataaaatctatttcatatagttttatttaaatatatatatttaagactaacatgcttttggatttcttttgcttttctatatagTAC
ACTTCATTTTTTGAATTTAATCATCACCTAGAGTCTATAATGGACAAAGCAT
ATATCTACAGgtaaagtataactcagtatacttgggggaaggggaaaaagcaatggtacaacattttagac ggaat
ttggcagg   
 Table 36: Sequences of cloned constructs in this study 
purple: Eco R1 binding site; green: primer; grey highlighted: exon; red highlighted: mutation site; yellow highlighted: 
SNP; blue: Bam H 
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Variant Size 
(bp) 
Sequence 
Exon 9 
ABCA4 
1239+1G>C 
194 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAACCTGGAGATCTCCCG
AGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACA
GAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
 
 308 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAAGCCTGGAGTCAAATC
CTTTAACCAAAATCGCTTGGAGGGCGGCAAAGCCTTTGCTGATGGGAAAAATCC
TGTACACTCCTGATTCACCTGCAGCACGAAGGATACTGAAGAATACCTGGAGAT
CTCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAG
AGACAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
  
334 
 
WT (see Table 33) 
  
377 
 
TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAcaatggggagtttctgtaaaatctgtcc
cttgtctcctggcagCATCCTTTTGTAATGCATTGATCCAGAGCCTGGAGTCAAATCCTTT
AACCAAAATCGCTTGGAGGGCGGCAAAGCCTTTGCTGATGGGAAAAATCCTGTA
CACTCCTGATTCACCTGCAGCACGAAGGATACTGAAGAATACCTGGAGATCTCC
CGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGA
CAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
  
454 
 
TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCACATCCTTTTGTAAT
GCATTGATCCAGAGCCTGGAGTCAAATCCTTTAACCAAAATCGCTTG
GAGGGCGGCAAAGCCTTTGCTGATGGGAAAAATCCTGTACACTCCT
GATTCACCTGCAGCACGAAGGATACTGAAGAAT tcatcactggaa tgct t tgct t
cagtgGGATCCcagatATCTGGTGATCCCGTACCTGTGTGGAAGGAAGCA
ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATAC AGA
GACCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAA
GGTGGAGAGAGAGACAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
  
496 
 
Unknown 
 
 607 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCACATCCTTTTGTAAT
GCATTGATCCAGAGCCTGGAGTCAAATCCTTTAACCAAAATCGCTTG
GAGGGCGGCAAAGCCTTTGCTGATGGGAAAAATC CTGTACACTCCT
GATTCACCTGCAGCACGAAGGATACTGAAGAAT g taagatcccagctgggc t t
gcct tgt gt accctggacctcccagaagtgtgtgtgtgtgtgtgtgtgtgt gagagagatgtgcct t cctg
gtagcacat ct catgt t t gt t t t t t gct aagtggactct tgcgt t t cc tcccccatccacagtcat cac tgga
atgct t t gct tcagtg GGATCCCAGATATCTGGTGATCCCGTACCTGTGTGGAAGGAA
GCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGACCT
GGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGG
AGAGAGAGACAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
 
Exon 30 
ABCA4 4354G>T 
 
194 
 
See above 
 304 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACTCAGCATACCCCTGTGGCAACTC
AACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCCAGAA
GCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGACCTGGAGATCTCCC
GAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGAC
AGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
  
308 
 
TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACTCAGCAGGAGTACCCCTGTGGC
AACTCAACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCC
AGAAGCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGACCTGGAGATC
81 
 
TCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAG
AGACAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
  
377 
 
TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCATACCCCTGTGGCAACTC
AACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCCAGAA
GCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGGTGCAGCACCAGGGA
GAAGCTCACCATGCTGCCAGAGTGCCCCGAGGGTGCCGGGGGCCTCCCGCCCCC
CCAGACCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAA
GAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGACCAATTCACTCCTCAG
GTG 
  
381 
 
WT (see Table 33) 
 
 407 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCATACCCCTGTGGCAACTC
AACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCCAGAA
GCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGGTACAGCACCAGGGA
GAAGCTCACCATGCTGCCAGAGTGCCCCGAGGGTGCCGGGGGCCTCCCGCCCCC
CCAGgtacctgacctccaaacaacggggccccagACCTGGAGATCTCCCGAGGGGACCCGACAG
GCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTC
GACCAATTCACTCCTCAGGTG 
 
 411 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGGAGTACCCCTGTGGC
AACTCAACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCC
AGAAGCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGGTACAGCACCA
GGGAGAAGCTCACCATGCTGCCAGAGTGCCCCGAGGGTGCCGGGGGCCTCCCGC
CCCCCCAGgtacctgacctccaaacaacggggccccagACCTGGAGATCTCCCGAGGGGACCCGA
CAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCC
ATTCGACCAATTCACTCCTCAGGTG 
 
 611 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCATACCCCTGTGGCAACTC
AACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCCAGAA
GCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGGTGCAGCACCAGGGA
GAAGCTCACCATGCTGCCAGAGTGCCCCGAGGGTGCCGGGGGCCTCCCGCCCCC
CCAGgtacctgacctccaaacaacggggccccaggtctgcctgccacagagggactaggggagtccctggtatctcctgagtct
ctcacaaactaacatttcaaactggcagttgagtaggggacTAAACCAAACTCCCTGCACCGGATCCCAG
ATATCTGGTGATCCCGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTG
CATCAGATGCTAAAGCATATGATACAGAGACCTGGAGATCTCCCGAGGGGACCC
GACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGAT
CCATTCGACCAATTCACTCCTCAGGTG 
 
 615 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGGAGTACCCCTGTGGC
AACTCAACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCC
AGAAGCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGGTGCAGCACCA
GGGAGAAGCTCACCATGCTGCCAGAGTGCCCCGAGGGTGCCGGGGGCCTCCCGC
CCCCCCAGgtacctgacctccaaacaacggggccccaggtctgcctgccacagagggactaggggagtccctggtatctcct
gagtctctcacaaactaacatttcaaactggcagttgagtaggggacTAAACCAAACTCCCTGCACCGGATCC
CAGATATCTGGTGATCCCGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTT
GTGCATCAGATGCTAAAGCATATGATACAGAGACCTGGAGATCTCCCGAGGGGA
CCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACA
GATCCATTCGACCAATTCACTCCTCAGGTG 
 
 
Exon 30 
ABCA4 4457C>T 
 
194 See above 
 308 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACTCAGCAGGAGTACCCCTGTGGC
AACTCAACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCC
AGAAGCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGACCTGGAGATC
82 
 
TCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAG
AGACAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
 
 381 WT (see Table 33) 
 
 411 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGGAGTACCCCTGTGGC
AACTCAACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCC
AGAAGCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGGTACAGCACCA
GGGAGAAGCTCACCATGCTGCCAGAGTGCCCCGAGGGTGCCGGGGGCCTCCCGC
CCCCCCAGgtacctgacctccaaacaacggggccccagACCTGGAGATCTCCCGAGGGGACCCGA
CAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCC
ATTCGACCAATTCACTCCTCAGGTG 
 
 615 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGGAGTACCCCTGTGGC
AACTCAACACCCTGGAAGACTCCTTCTGTGTCCCCAAACATCACCCAGCTGTTCC
AGAAGCAGAAATGGACACAGGTCAACCCTTCACCATCCTGCAGGTGCAGCACCA
GGGAGAAGCTCACCATGCTGCCAGAGTGCCCCGAGGGTGCCGGGGGCCTCCCGC
CCCCCCAGgtacctgacctccaaacaacggggccccaggtctgcctgccacagagggactaggggagtccctggtatctcct
gagtctctcacaaactaacatttcaaactggcagttgagtaggggacTAAACCAAACTCCCTGCACCGGATCC
CAGATATCTGGTGATCCCGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTT
GTGCATCAGATGCTAAAGCATATGATACAGAGACCTGGAGATCTCCCGAGGGGA
CCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACA
GATCCATTCGACCAATTCACTCCTCAGGTG 
 
Exon 33_34 
ABCA4 
4773+3A>G 
 
194 
 
See above 
 
 269 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGGCCCTATCACTAG
AGAGGCCTCTAAAGAAATACCTGATTTCCTTAAACATCTAGAAACTG
AAGACAACATTAAGACCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAA
GGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGACCAA
TTCACTCCTCAGGTG 
 
 291 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGTATGGAGGAATTT
CCATTGGAGGAAAGCTCCCAGTCGTCCCCATCACGGGGGAAGCACT
TGTTGGGTTTTTAAGCGACCTTGGCCGGATCATGAAT  
ACCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAG
GTGGAGAGAGAGACAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
 
 300 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGTATGGAGGAATTT
CCATTGGAGGAAAGCTCCCAGTCGTCCCCATCACGGGGGAAGCACT
TGTTGGGTTTTTAAGCGACCTTGGCCGGATCATGAATGTGAGCGGG A
CCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGG
TGGAGAGAGAGACAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
 
 375 WT (see Table 33) 
 
 
 
 
Exon 35 
ABCA4 4919G>A 
 
 
 
194 
 
 
 
See above 
 294 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCA 
GCCAGCCTGCCTAAGGACAGGAGCCCCGAGGAGTATGGAATCACCG
TCATTAGCCAACCCCTGAACCTGACCAAGGAGCAGCTCTCAGAGATT
ACAGTACCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAG
83 
 
AAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGACCAATTCACTCCTC
AGGTG 
 
 364 WT (see Table 33) 
 
 464 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCActaccaaacccttcctgcttctcaaattt
cctttccttcactgatttctgctttaactagctgttagtgcagcgtctcagatgtcctctccaccctctagGTGTGGTTTAATAA
CAAAGGCTGGCATGCCCTGGTCAGCTTTCTCAATGTGGCCCACAACGCCATCTTA
CGGGCCAGCCTGCCTAAGGACAGGAGCCCCGAGGAGTATGGAATCACCGTCATT
AGCCAACCCCTGAACCTGACCAAGGAGCAGCTCTCAGAGATTACAGTACCTGGA
GATCTCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGA
GAGAGACAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
 
 538 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGTGTGGTTTAATAACAA
AGGCTGGCATGCCCTGGTCAGCTTTCTCAATGTGGCCCACAACGCCATCTTACGG
GCCAGCCTGCCTAAGGACAGGAGCCCCGAGGAGTATGGAATCACCGTCATTAGC
CAACCCCTGAACCTGACCAAGGAGCAGCTCTCAGAGATTACAGTgtaagccaccacagcc
ccagcctcaccactttcttgtcaccttctccactctttgaacatcctgagaggattctcaccaccGGATCCCAGATATCTG
GTGATCCCGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGA
TGCTAAAGCATATGATACAGAGACCTGGAGATCTCCCGAGGGGACCCGACAGGC
CCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCG
ACCAATTCACTCCTCAGGTG 
 
Exon 35 
ABCA4 5018+2T>C 
194 See above 
 364 WT (see Table 33) 
 
 495 Unknown 
 
 538 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGTGTGGTTTAATAA
CAAAGGCTGGCATGCCCTGGTCAGCTTTCTCAATGTGGCCCACAACG
CCATCTTAC GGGCCAGCCTGCCTAAGGACAGGAGCCCCGAGGAGTA
TGGAATCACCGTCATTAGCCAACCCCTGAACCTGACCAAGGAGCAG
CTCTCAGAGATTACAGT gtaagccaccacagccccagcctcaccact t tc t tg tcacct t c t c
cact c t t t gaacatcctgagagga t t c tcaccacc GGATCCCAGATATCTGGTGATCCCGTA
CCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCA
TATGATACAGAGACCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGAA
TAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGACCAATTCA
CTCCTCAGGT 
 
 606 unknown 
 
Exon 49 
ABCA4 6732G>A 
 
281 
 
WT (see Table 33) 
  
 
 
 
 
74 
 
 
 
 
 
 
TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAGTGTTTGTAAATTTTGCT
AAACAGCAGACTGAAAGTCATGACCTCCCTCTGCACCCTCGAGCTGCTGGAGCC
AGTCGACAAGCCCAGgtacccctgctgcttatgcagtccacagcttgaggcagttccttggctcagagcccagctggtt
cactgggcttgagttgCTCCAAGGCTCAGATATGCCGGATCCCAGATATCTGGTGATCCCG
TACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAG
CATATGATACAGAGACCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGG
AATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGACCAATT
CACTCCTCAGGTG 
 
84 
 
Exon 9 
CNGB 991-3T>G 
259 WT (see Table 33) 
 261 TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGC
ACTGTGACAAGCTGCACGCTCTAGAGTCGACCCAGCAagTACACTTCATTTTTTG
AATTTAATCATCACCTAGAGTCTATAATGGACAAAGCATATATCTACAGACCTG
GAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGA
GAGAGAGACAGAGACAGATCCATTCGACCAATTCACTCCTCAGGTG 
Table 37: Sequences of all splicing transcripts in this study 
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Abbreviation Meaning 
’ Prime 
° C Degree Celcius 
A Acceptor 
A2E Lipofuscin fluorophore in retinal pigmented 
epithelial 
AAP Antarctic alkaline phosphatase 
ABCA4 ATP-Binding cassette, subfamily A, member 4 
AMD Age-related macular dystrophy 
Amp Ampicillin 
AS Acceptor site 
ATP Adenosine triphosphate 
BamH1 Bacillus amyloliquefaciens, type II restriction 
endonuclease 
Bp Base pair 
cDNA Complementary DNA  
cf Confer “compare to” 
cGMP Cyclic guanosine monophosphate 
cm Centimeter 
CNGA3 Cyclic nucleotide gated channel alpha 3 
CNGB3 Cyclic nucleotide gated channel beta 3 
CORD Cone-rod dystrophy 
CRX Cone-rod homeobox 
D Donor 
DH5α E. coli competent cell strain - “D.H.” Doug 
Hanahan, Bethesda Research Laboratories, 1986 
DMEM Dulbecco`s Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
DS Donor site 
ECD Extracellular domain 
E. coli Escherichia coli 
EcoR1 Escherichia coli, strain R, endonuclease I 
Exo Exonuclease I 
EDTA Ethylendiamintetraacetic acid 
Et al.  et alii 
FCS Fetal calf serum  
FF Fundus flavimaculatus 
h Hour 
HGMD Human Gene Mutation Database 
H2O Water 
K Potassium 
kb Kilobase 
KCNV2 Potassium channel, subfamily V, member 2 
kDA Kilodalton 
l Litre 
LB Liquid broth  
MAF Minor allele frequency 
86 
 
MgSO4 Magnesium sulfate 
min Minute 
ml Millilitre 
MM Master mix 
mM Millimolar 
mRNA Messenger ribonucleic acid 
Mut Mutant 
Na Sodium 
NaCl Sodium chloride 
ng Nanogram 
Nm Nanometer 
NRPE N-retinylidenephosphatidylethanolamine 
P/S/G Penicillin/Streptomycin/Glutamine 
PB Phosphate buffer  
PBS Phosphate buffered saline  
PCR Polymerase chain reaction  
Pen/Strep Penicillin/Streptomycin 
pGEM Cloning vector system 
PROM1 Proamin 1 
RNA Ribonucleic acid 
RP Retinitis pigmentosa 
RPE Retinal pigment epithelium 
RPGR Retinitis pigmentosa GTPase regulator 
rpm Rotations per minute 
RT Room temperature 
RT-PCR Reverse Transcriptase PCR 
SDS Sodium dodecyl sulfate  
sec Second 
STGD Stardardt disease 
TBE Tris/Borate/EDTA 
Tris Tris(hydroxymethyl)aminomethane 
µg Microgram 
µl  Microlitre 
UV Ultraviolet 
V Volt 
VTotal Total volume 
VIC Voltage-gated ion channels 
WT Wild-type 
Table 38: Abbreviations used in text 
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Company Name 
   
Headquarters 
 
Abimed 
    
Langenfeld, Germany 
 
AppliChem 
    
Darmstadt, Germany 
 
Applied Biosystems 
   
Darmstadt, Germany 
 
B.Braun Biotech 
   
Melsungen, Germany 
 
BDK GmbH 
   
Sonnenbühl, Germany 
 
Becton, Dickson & Co. 
   
Heidelberg, Germany 
 
Biolabs 
    
Ipswich, MA, USA 
 
Biometra 
    
Goettingen, Germany 
 
Biomol 
    
Hamburg, Germany 
 
Biostep 
    
Jahnsdorf, Germany 
 
Biozym 
    
Hessisch Oldendorf, Germany 
Brand 
    
Wertheim, Germany 
 
Braun 
    
Melsungen, Germany 
 
Carl Roth 
    
Karlsruhe, Germany 
 
Corning, Inc. 
   
Amsterdam, The Netherlands 
Daewoo 
    
Berkshire, England 
 
eppendorf 
    
Hamburg, Germany 
 
Feather 
    
Osaka, Japan 
 
Genaxxon Bioscience 
   
Ulm, Germany 
 
GFL 
    
Burgwedel, Germany 
 
Gibco 
    
Grand Island, NY, USA 
 
Inst.Human Genetics UR 
   
Regensburg, Germany 
 
Invitrogen 
    
Grand Island, NY, USA 
 
KIMTECH 
    
Neenah, WI, USA 
 
Lauda 
    
Lauda-Königshofen, Germany 
Macherey-Nagel 
   
Düren, Germany 
 
Memmert 
    
Schwabach, Germany 
 
Merck 
    
Darmstadt, Germany 
 
Millipore 
    
Darmstadt, Germany 
 
Mirus 
    
Madison, WI, USA 
 
NanoDrop® 
   
Wilmington, DE, USA 
 
Orange Scientific 
   
Braine-l'Alleud, Belgium 
 
PAA 
    
Freiburg, Germany 
 
Promega 
    
Madison, WI, USA 
 
Qiagen 
    
Venol, The Netherlands 
 
Qualitron 
    
Karachi, Pakistan 
 
Sarstedt 
    
Nümbrecht, Germany 
 
ScientificIndustries 
   
Bohemia, NY, USA 
 
Scotsman 
    
Vernon Hills, IL, USA 
 
Serva 
    
Heidelberg 
  
Sigma 
    
St. Louis, MO, USA 
 
Systec GmbH 
   
Wettenberg, Germany 
 
ThermoScientific 
   
Waltham, MA, USA 
 
Thieme Labortechnik  
   
Bensheim, Germany 
 
VWR 
    
Darmstadt, Germany 
 
Table 39: Company name and headquarters  
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